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Sammendrag 
Kreft er en sykdom som oppstår når en mutert celle vokser og deler seg, uavhengig av 
plassrestriksjoner eller tilgang på næring. Dette lager et indre press på andre organer i 
kroppen, hvis det ikke blir behandlet. I dag har vi ingen behandlingsform som dreper kreft 
uten at vi selv blir syke, derfor er det viktig å utarbeide nye kreftmedisiner for å fjerne 
kreftcellene mer effektivt I tillegg til effektiv celledeling, produserer kreftceller molekyler av 
andre sammensetninger og konsentrasjoner sammenlignet med friske celler. Denne 
kunnskapen utnyttes i immunterapi, hvor kroppens eget immunforsvar blir stimulert til å 
angripe kreftcellene. Et molekyl som kun eksisterer på celleoverflaten til kreft hos voksene 
mennesker, er gangliosidet NeuGc GM3. Dette gangliosidet blir gjenkjent av et antistoff med 
navnet 14F7, med kallenavnet Snikmorderen fordi det kun dreper kreftceller. Når 14F7 binder 
til gangliosidet, starter cellen å svulme, sprekke opp, og dø. Dette gjør 14F7 spesielt attraktiv 
for fremtidig kreftbehandling, siden den spesifikt dreper kreft celler. For å videreutvikle 14F7 
og øke kunnskapen for hvordan antistoffer gjenkjenner karbohydratbaserte molekyler, må vi 
først kartlegges hvordan 14F7 interagerer med NeuGc GM3 gangliosidet. Strukturen til 14F7s 
fragment, antigen-bindende (Fab) ble kjent i 2004 ved hjelp av røntgenkrystallografi. På tross 
av iherdig innsats var det ikke mulig å reprodusere Fab krystallen, derfor finnes det i dag ikke 
et eksperimentelt svar på hvor og hvordan gangliosidet assosieres med 14F7. For å løse dette 
mysteriet prøves en ny vinkling, hvor 14F7 single-chain variable fragmenter (scFvs) blir 
uttrykt i periplasma til E. coli. scFv er det minste fragmentet som fortsatt inneholder det 
komplette bindingssete til gangliosidet. Siden scFv er mindre komplekst, sammenlignet med 
Fab og det komplette antistoffet, er det en lovende kandidat for å karakterisere interaksjonene 
mellom 14F7 og NeuGc GM3 gangliosidet ved bruk av røntgenkrystallografi. Fire forskjellige 
varianter av scFv 14F7 ble klonet og transformert inn i E. coli, hvor de ble isolert fra 
periplasma og renset med affinitetskromatografi. Bindingen til gangliosidet ble testet, siden 
konstruktene ikke gjenkjente gangliosidet ble scFv konstruktene optimalisert. Resultatet ble 
funksjonelle scFv proteiner med affinitet for NeuGc GM3. 14F7 scFv proteinene ble brukt til 
å utføre ELISA, ThermoFluor, SPR og krystalliseringsstudier. Vi klarte å gro krystaller, men 
fikk ikke brukbare diffraksjonsdata. Systemet trenger derfor å bli optimalisert videre. Denne 
masteroppgaven danner et grunnlag for videre arbeid både for krystalliseringsstudier, men 
også for hvordan ulike scFv design påvirker proteinets stabilitet og uttrykking i prokaryote 
celler.  
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Abstract 
Cancer is a disease that can develop from any cell within our body. Today, there is no 
commensally available cancer medicine that kills the cancer effectively, without harming 
healthy human cells. When a healthy cell mutates into a cancerous cell, it exhibits 
uncontrolled proliferation and expresses molecules in a different ratio. This information can 
be used in cancer immunotherapy for diagnostics and therapeutic purposes. Immunotherapy 
exploits the tumour’s unique cytogenetics and stimulates the immune system to destroy it by 
targeting biomarkers produced by the tumour. One such marker is the N-glycolyl GM3 
(NeuGc GM3) ganglioside located on the cell surface. The ganglioside is recognised by a 
monoclonal antibody (mAb) named 14F7, nicknamed The Assassin, because it specifically 
recognises and kills tumours. When the antibody binds, it results in cell-swelling and lesion 
formation, thereby killing the cell. To fully exploit the favourable properties of 14F7, it is 
important to know exactly how the antibody interacts with the NeuGc GM3 ganglioside. This 
information can be used to produce the next-generation of 14F7 and give general insight into 
antibody-ganglioside recognition. 
The structure of the 14F7 fragment, antigen-binding (Fab) was solved by X-ray 
crystallography in 2004, and the ganglioside binding was predicted in a docking model. 
Despite significant effort, it was not possible to reproduce the Fab crystals. Consequently, the 
mystery of how 14F7 binds to the NeuGc GM3 ganglioside is still not solved experimentally. 
Therefore, a new approach is tested using the single-chain Fv (scFv), the smallest antibody 
fragment containing the whole binding site. Because a scFv is less complex, and easier to 
obtain in larger amounts, the scFv is an excellent candidate for studying the binding 
characteristics by X-ray crystallography. Four different scFv versions of the 14F7 were 
cloned and transformed into E. coli. They were isolated from the periplasm and purified using 
affinity chromatography. The binding activity to the NeuGc GM3 ganglioside was tested by 
enzyme-linked immunosorbent assay (ELISA). Since no activity was detected, the constructs 
were optimised. The new scFv constructs displayed affinity towards NeuGc GM3 ganglioside 
and were subjected to crystallographic studies, SPR and ThermoFluor. We were able to obtain 
crystals, but since they did not diffract, further optimisation is needed. To date, we have 
achieved to produce three functional 14F7 scFvs versions that crystallise. These can be used 
as tools for further study, both with respect to crystallographic studies and to obtain insight 
into how scFv designs affect expression yields and molecular stability.  
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1 Introduction 
1.1 Cancer disease 
Tumour formation involves abnormal cell growth that may either be restricted within its 
originating tissue (benign tumour), or as malignant tumour, capable of spreading throughout 
the body and invading other tissues (metastasis). A malignant tumour is often referred to as 
cancer, but cancer cannot always be classified as tumours, as in the case of early stage blood 
cancer. Cancer exhibit defects in the signal transduction pathways, causing uncontrolled 
proliferation. While healthy cells only divide 20 to 60 times in culture before they die, cancer 
cell are immortal (Voet and Voet, 2011). Several somatic events, or a serial of germ line 
mutations, can lead to alteration of cancer suppressor genes, oncogenes or microRNA (Croce, 
2008, Stoler et al., 1999). Such genetic alterations are often a result of chemical 
carcinogenesis, radiation or certain viruses (Voet and Voet, 2011). When a healthy cell 
mutates into a cancerous cell it is not only the growth regulation that is affected. Cancer cells 
also express a high diversity of molecules in other ratios and compositions compared to 
healthy cells. Cancer can develop in almost any organ or tissue. The treatments are diverse, 
depending on the type of tumour and the stage of progression. 
1.1.1 Cancer treatment 
There are four main methods used today to treat cancer: surgery, radioactive therapy, 
chemotherapy and immunotherapy. In order to produce a synergetic effect surgery is often 
combined with one or a subset of different therapeutic methods. The most common method to 
treat cancer is radioactive therapy, using high-energy radiation to damage the DNA leading to 
cell death. Radiation damage to the genome is most effective during cell division. Since 
cancer cells divide more rapidly, radiation damage accumulates in their DNA faster compared 
to healthy cells, killing the cancer cells. Chemotherapy uses pharmaceutically produced drugs 
to target molecular processes during cell division, thereby killing the cancer. Since the 
therapy affects the whole body, all cells are exposed, and especially the fast dividing cells in 
the digestive tract, bone marrow and hair follicles. 
  
2 
Immunotherapy  
Another diagnostic and therapeutic method acknowledged as one of the four major cancer 
treatments is immunotherapy. Cancer immunotherapy is developing rapidly and has become 
one of the major fields within cancer treatment, immunotherapy exploits the tumour’s unique 
cytogenetics and directly or indirectly stimulates the immune system to destroy the cancer by 
targeting biomarkers exclusively produced by cancers (tumour-specific antigens) or 
molecules found in higher abundance compared to regular cells (tumour-associated antigens). 
The innate and adaptive immune systems in humans have the ability to recognise and kill 
cancers (Parish, 2003). Through immunoselective processes, tumours become highly resistant 
against the host’s immune system and the body can no longer fight the tumours on its own 
(Fenton and Longo, 1995). The heterogeneity of tumours makes it difficult to treat cancer 
even within the same diagnostic type. Information about general epitopes and treatments 
targeting tumour antigens are therefore at high demand. Since these molecules are often 
intracellular, they are not very accessible for the immune system (Fenton and Longo, 1995). 
Fortunately, some tumour antigens are located on the cell surface, for example the N-glycolyl 
GM3 ganglioside. This tumour-specific antigen is identified in several different types of 
human tumours and is therefore a prime target for diagnostic and therapeutic treatments 
(Blanco et al., 2011b, Blanco et al., 2011a, Blanco et al., 2012, Blanco et al., 2013, Scursoni 
et al., 2011). 
Modern immunotherapy includes a diversity of methods. Generally, cancer immunotherapy 
can be divided into two classes: active and passive immunotherapy. The active form of 
immunotherapy often targets the cancer indirectly, using an active vaccine, or using adaptive 
cell transfer, where isolated tumour-reactive lymphocytes are stimulated ex vivo before being 
re-introduced into the cancer-bearing host, giving prolonged immunity (Dudley and 
Rosenberg, 2003). Passive immunotherapy, of which antibody-based immunotherapy is one 
example, targets the cancer in a more direct manner. In antibody-mediated immunotherapy, 
antibodies manufactured outside the body are injected into the patient. The antibodies 
recognise cancer-associated or tumour-specific antigens, but do not give any prolonged 
immunity. The natural effector mechanisms of the antibodies used in cancer therapy may 
trigger the body’s own immune system to attack the cancer cells. Another alternative is to 
couple the antibody to a radioactive or toxic molecule, inducing cell death. Due to very high 
costs and side effects in the range of mild to severe, combined with the increased awareness 
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in the difficulties in identifying responders from non-responders, very few antibody-based 
cancer drugs are approved as first-line treatments. Moreover, despite the fact that many of 
these antibodies offer significant clinical advantages, their influence is difficult to assess and 
in most cases, the treatment only slightly affects the overall survival. Thus, advanced cancer 
treatment today involves a careful stepwise process in which the anti-cancer weapon arsenal is 
gradually exploited within the course of treatment to prolong the therapeutic window.  
Most antibodies approved for cancer treatment today do not target the cancer cells directly, 
instead they recognise tumour-associated antigens, one example being the antibody 
bevacizumab (Avastin
™
), targeting a vascular endothelial growth factor signal. Bevacizumab 
was approved by the Food and Drug Administration in USA, 2013 for metastatic colorectal 
cancer treatment in combination with chemotherapy. All antibodies recognising tumour-
associated molecules also target the host’s healthy cells in some extent. The consequence is 
both dampening the therapeutic effect due to sink effects, as well as resulting in potentially 
side effects due to off-target effector functions. Another example is the FDA approved 
antibody rituximab (MabThera™), a cell-lineage specific antibody targeting the CD20 
molecule found on virally all B cells, and thus is used to treat B cell lymphomas. Here, 
complete compartment depletion resulting in a constitutive immune-compromised state of the 
patient is a direct result of the intervention. Antibodies recognising cancer-specific antigens 
have major advantages, as they do no damage the host’s healthy cells, but since cancer cells 
originate from the host itself there are a limited number of unique epitopes available. 
Therefore, antibodies recognising these tumour-specific antigens are of special importance. 
One such antibody with a promising potential in therapeutic treatments is 14F7 recognising a 
tumour-specific antigen, namely the ganglioside NeuGc GM3. Since the ganglioside can be 
defined as non-self the therapeutic effect will not be reduced by the hosts own immune 
system, and the negative side effects are reduced, since the antibody can separate between 
host cells and cancer cells. This gives hope for the production of an effective cancer medicine 
and optimally a cancer vaccine, quenching the cancer in its early phase. 
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1.2 Gangliosides as tumour antigens 
The molecular composition covering the cell surface is partially tissue specific and can be 
used to identify cell function. Gangliosides cover the cell surface of all animal cells and have 
multiple functions. They are important for cell-cell interaction, cell-adhesion, development, 
differentiation, inflammation, signal transduction, tumour progression and more (Hakomori, 
2002, Stults et al., 1989). Gangliosides consist of a lipid and a carbohydrate moiety: a 
sphingolipid and a carbohydrate containing one or more sialic acid residues. The hydrophilic 
carbohydrate region is exposed to the outer environment of the cell, while the sphingolipid 
portion anchors the ganglioside to the membrane. With the negative charge of the sialic acids, 
the glycosphingolipids contribute to the outer negative charge of the cells. 
N-acetylneuraminic acid (NeuAc) and N-glycolyl neuraminic acid (NeuGc) are the most 
common types of sialic acids in vertebrates. While most vertebrates express both NeuAc and 
NeuGc gangliosides, healthy chicken and human tissues express minimal levels of NeuGc 
gangliosides (Malykh et al., 2001). The small traces of NeuGc ganglioside found in human 
tissue might be explained as exogenous incorporation from the diet (Tangvoranuntakul et al., 
2003, Bardor et al., 2005). The exception is human foetal tissue and several different tumour 
tissues where NeuGc gangliosides are localised in large amounts. How these cells acquire the 
NeuGc gangliosides is still a mystery but this makes NeuGc gangliosides a molecular marker 
and an excellent target for cancer treatment (Malykh et al., 2001, Marquina et al., 1996). 
NeuGc differs from NeuAc by an extremely subtle chemical modification, the addition of a 
single oxygen atom at the C5 position of the NeuGc (see Figure 1). The NeuAc gangliosides 
can be converted to NeuGc gangliosides by a hydroxylase enzyme present in most 
vertebrates, including chimpanzees (Muchmore et al., 1998). Healthy human tissues are 
genetically deficient in producing NeuGc due to a homozygous deletion of 92 base pairs 
within the active site of the CMP-N-acetylneuraminic acid hydroxylase (cmah) enzyme 
(Varki, 2001). This Alu-mediated inactivation happened between 2.5 and 3 million years ago, 
leading to a frame shift in the in the human cmah gene, thereby cancelling NeuGc production 
in humans (Chou et al., 1998, Irie et al., 1998, Chou et al., 2002). The loss of NeuGc in 
humans was followed by a correspondent increase of NeuAc ganglioside expression (Varki, 
2001). Many pathogens use sialic acids as binding sites, so removal of NeuGc gangliosides 
from the cell surface has probably played an important role for the evolution of human 
interacting pathogens. The deletion is detected in all human populations studied to date and 
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might be due to a negative selection by a lethal pathogen that selectively recognised NeuGc 
(Chou et al., 1998, Gagneux and Varki, 1999). Today, several antibodies are developed for 
recognising NeuGc gangliosides as a method to diagnose tumours. One such NeuGc 
ganglioside is NeuGc GM3. This ganglioside is specifically recognised by a monoclonal 
antibody (mAb) named 14F7. The antibody is today used in diagnostic and therapeutic 
methods to fight tumour growth in humans.  
 
 
Figure 1: NeuGc(Ac) GM3 ganglioside. The figure was published by Ute Krengel et al. (Krengel et al., 2004) 
The R-group represents the difference between NeuAc GM3 and NeuGc GM3 gangliosides where NeuGc GM3 
gangliosides are produced mainly in human cancer cells, while NeuAc GM3 gangliosides can be found in all 
human cells. 
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1.3 Anti-tumour Antibodies 
1.3.1 The immune system 
The immune system is a collection of defence systems protecting an organism against 
diseases and harmful transformations. In vertebrates, it can be separated into two main 
categories. The innate system is the organism’s primary defence. It is an assembly of physical 
barriers as for example skin and mucus membranes, the complement system and a variety of 
defence cells: macrophages, monocytes, phagocytes, NK cells, mast cells and more. The 
second category of defence is the adaptive immune system, primarily involving T and B 
lymphocytes (B cells). There is a delicate interplay and inter-dependency between the innate 
and adaptive immune system and many immune cells may be assigned to both arms. The 
adaptive immune system targets pathogens by recognising the molecular differences between 
self and non-self, making it possible for vertebrates with slow evolutionary development to 
keep up with the fast-evolving pathogens. The chief molecules responsible are the T-cell 
receptors produced by the T cells, and antibodies produced by B cells. Every antibody 
contains a unique non-self paratope that might help the vertebrate defend itself against 
invading pathogens. Antibodies evolve by somatic rearrangement resulting in a very high 
diversity of unique binding specificities. The variable light chain DNA undertakes one 
rearrangement of the variable (V) and joining (J) gene segment, while the variable heavy 
chain DNA is formed via two rearrangements. First the J-segment and the diverse (D) gene 
segment are rearranged, then the resulting JD-segment goes through a second rearrangement 
with the V-segment. In humans, this results in over 1.5 × 10
7
 antibodies with different 
specificity, and this number does not include the extra diversity obtained by somatic 
mutations (Nelson, 2008). Thus, the actual diversity of antibody specificities present at a 
given time point is thought to be in a range exceeding 10
10
. Native B cells produce 
membrane-bound antibodies of subclass IgM and IgD. In a later stage, B cells can secrete 
IgM pentamers known for their high avidity, but low affinity for the antigen (Ehrenstein and 
Notley, 2010). In order to get a high-affinity antibody, the antibody-producing B cells must 
undergo somatic hypermutation where new mutations are introduced in the antibody’s DNA. 
This process take place in specialised structures called germinal centres, developing in the 
secondary lymphoid organs and is dependent on the assistance of T-helper cells and follicular 
dendritic cells. Somatic hypermutation primarily occurs within three complementarity-
determining regions (CDR). The complementarity-determining region number 3 (CDR3) of 
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the heavy chain has been shown to be of special importance for antigen binding. It consists of 
the C-terminus part of the J-segment, the N-terminus fragment of the V-segment, together 
with the whole D-segment. The second round of selection is followed by isotypic switching. 
The IgM and IgD subclass DNA is deleted, driving the B cell into producing antibodies with 
the same antigen specificity, but coupled to a different subclass. Depending on the site of the 
infection, the high-affinity antibodies can be of subclass IgA, IgE or IgG, where IgG is the 
most abundant in serum, and IgA dominates the mucosal surfaces. After activating an 
adaptive immune response, some B cells differentiate into memory cells. These cells have a 
prolonged lifetime, providing the host with immunity against the specific epitope. 
1.3.2 Immunoglobulin subclass G  
IgG is a heterotetrameric molecule consisting of two identical heavy and light chains shaped 
like a Y (Figure 2, and a 3 dimensional model in Figure 3). The heavy chain folds into four 
structural domains: VH, CH1, CH2 and CH3, while the light chain folds into two structural 
domains: VL, and CL, as reviewed by Davies and Chacko (Davies and Chacko, 1993). The 
constant (C) domains have the characteristic immunoglobulin fold consisting of 3+4 
antiparallel β-sheets forming a β-sandwich, while the variable (V) domains consist of an 
immunoglobulin fold composed of a 4+5 antiparallel β-sheet sandwich. The four chains fold 
into three structural units, defined by proteolytic cleavage by papain. There are two identical 
units called the antigen-binding fragments (Fab), each consisting of the CH1, CL and the VH, 
VL subunits. The two Fab units are both connected to the third unit through a flexible hinge 
region. The third unit is called the crystallisable fragment (Fc) because it crystallises more 
easily. Fc consists of two CH2 and CH3 subunits. The CH3/CH3, CH1/CL and VH/VL subunits are 
connected with numerous non-covalent hydrophobic interactions, while the two CH2 subunits 
are associated through hydrophilic interactions, due to N-glycosylation of Asp297 of both the 
CH2 domains (Jefferis, 1990). Every domain also contains one internal disulphide bridge, 
increasing its stability. Disulphide bridges also help holding the different chains together. The 
heavy chains are covalently connected by disulphide bridges localised in the hinge region 
between CH1 and CH2, and the light and heavy chains are connected with a disulphide bridge at 
the C-terminus of CH1 and CL.  
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Fabs can be further divided into a constant and a variable fragment. The VH and VL are 
together called the variable fragment (Fv). It contains the complete antigen binding site, 
primarily localised in six complementarity-determining regions (CDRs), three in each domain 
(Poljak, 1973). Compared to the Fv, an isolated Fab has a very slow unfolding rate, caused by 
mutual stabilisation between the variable and constant domains (Röthlisberger et al., 2005). 
Because of the low stability of the Fv, construct engineering techniques have evolved to 
improve Fv stability. One such has been the introduction of a soluble and flexible 15-25 
amino acid linker, connecting the two variable domains. The resulting fragment was named 
single-chain Fv fragment (scFv) (Bird, 1988). The scFv construct has revolutionised the 
crystallisation field because of its small size, and low complexity (Wörn and Plückthun, 
2001). The scFv should optimally have the same binding affinity as the whole antibody. 
However, most often this is not the case, due to the increased entropy-dependent penalty that 
transpire when the stabilisation provided by the constant domains are removed. Even with a 
linker connecting the two variable domains, the scFv often remains unstable, and tends 
denature and aggregate at higher rates compared with Fab and mAb. Therefore, assessment of 
linker length and sequence, as well as expression and isolation techniques, are important for 
optimisation of antibody production (Wörn and Plückthun, 2001).  
In humans, antibodies of subclass Immunoglobulin (Ig) G are one of the most abundant 
proteins in the blood serum (Nelson, 2008). IgG antibodies are widely used in diagnostic and 
therapeutic methods because of their binding specificity, and their advantage of interacting 
with the complement system, resulting in a strong therapeutic effect. IgG has an especially 
long half-life in serum due to interaction with the neonatal Fc receptor (FcRn). The 
intracellular FcRn has in later years been shown to be almost ubiquitously expressed, and is 
the primary component mediating the exceptionally long serum half-life of the two most 
abundant serum proteins, namely albumin and IgG. FcRn binds internalised IgG at low pH in 
the acidified endosomal compartment and re-routs it back to the cell surface for release at 
physiological pH, thus rescuing the cargo from lysosome degradation (Cohen-Solal et al., 
2004, Goebl et al., 2008).  
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Figure 2: An IgG model. Heavy chains are in blue and violet. Light chains in red and teal green. The constant 
domains (C) are in a darker colour tone than the variable domains (V). Sulphide bridges are annotated “S-S”. 
The carbohydrate moiety connected to CH2 is annotated as “CHO”.  
 
 
Figure 3: 14F7. The modified structure is adapted from Krengel et al. (Krengel et al., 2004), with heavy chains 
in blue/violet, light chains in red/teal green and CDRs in grey. The carbohydrate moiety is coloured light green. 
The Fab and Fc structures were visualised using PyMOL (Schrödinger) (PDB ID 1RIH), and fused MS Paint. 
The β-sheets are shown as arrows  
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1.3.3 The monoclonal antibody 14F7 
Monoclonal antibodies emerged as diagnostic and therapeutic agents in 1985 when the first 
murine monoclonal IgG2 Orthoclone OKT3 antibody was approved for human treatment by 
the United States Food and Drug Administration (Smith, 1996). Orthoclone OKT3 prevents 
the human body from rejecting solid organs during clinical transplantation. Since it was 
murine, it was only efficient for 3 weeks before it was inactivated due to the HAMA response. 
With time, antibodies recognising cancer antigens were discovered, and, in the year 2000, an 
IgG1 antibody, recognising the NeuGc GM3 ganglioside, was reported for the first time. The 
antibody was named 14F7 and was the first antibody of the IgG subclass recognising a 
ganglioside. (KD = 25 nM) (Rojas et al., 2004). 14F7 was generated by the Centre of 
Molecular Immunology in Havana, Cuba, by immunising Balb/c mice with a vaccine 
containing the NeuGc GM3 ganglioside hydrophobically conjugated to a human very-low-
density lipoprotein in the presence of Freund’s adjuvant. The Ig was obtained by a mature 
humoral response resulting in a hypermutated murine monoclonal IgG1 antibody (Carr A., 
2000). A chimeric version of 14F7 was made by cloning the variable domains of the murine 
14F7 onto human IgG1 and κ constant domains (Roque-Navarro et al., 2008). Although the 
constant part of the chimeric antibody was human, a chimeric antibody can still evoke a 
HAMA response. Therefore, the non-human epitopes in the variable domains of the chimeric 
14F7 were changed, producing a humanised 14F7. 
The selective binding of 14F7 is strictly restricted to NeuGc GM3 ganglioside with a binding 
affinity of KD = 25 nM, and does not interact with other NeuGc variants or the closely related 
NeuAc GM3 ganglioside (Carr A., 2000). The specificity of 14F7 mAb is dependent on both 
the sialic acid linkage and the external position of the N-glycolyl neuraminic acid group (Carr 
A., 2000). 14F7 mAb has been shown to inhibit growth of solid tumours and is an effective 
killer of cancer cells both in vitro and in vivo (Carr A., 2000, Carr A., 2002). Initially the 
antibody was targeted against breast cancer and melanoma, but today a wide range of cancers 
overexpressing the NeuGc GM3 ganglioside are known (Carr A., 2000). 14F7 mAb was 
demonstrated to be inefficient in killing cancers by more standard antibody pathways, as for 
example antibody-dependent cytotoxicity and complement-dependent cytotoxicity. (Carr A., 
2002). Instead, 14F7 can induce a non-apoptotic cell death resulting in loss of cytoskeleton 
integrity, cell swelling, and large membrane lesions (Roque-Navarro et al., 2008). The lesions 
are larger than the pores formed by complement, perforin or bacterial toxins (Geny and 
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Popoff, 2006). This mechanism resembles a complement independent oncosis that might be a 
consequence of ion pump failure (Majno and Joris, 1995). This oncosis-like cell death 
mechanism mediated by a certain group of antibodies is believed to be related to positive 
charges in the CDR3 region of the heavy chain (Bhat et al., 1997). The arginine motif 
described in the next section (Arg98-X-Arg100A-Arg100) matches the postulated description 
(Rodríguez et al., 2007). It is especially fascinating that isolated Fab fragments lose their 
cytotoxic function while F(ab)2
 
are still functionally active, suggesting that the binding sites 
might cooperate (Roque-Navarro et al., 2008). Today, 14F7 can for example be used in 
passive immunotherapy combined with chemotherapy or radiotherapy of solid tumours (Carr 
A., 2002). In 2006, 14F7 was included in a clinical phase (1 trial), where breast cancer 
patients were treated successfully with one dose (up to 3 mg) of murine 14F7 mAb, and today 
it has proceeded into phase 2 (Oliva et al., 2006). 
Rojas et at. failed to produce the 14F7 scFv in a bacterial expression system both as a soluble 
molecule and displayed on phage (Rojas et al., 2004). They therefore experimented with 
variable light chain shuffling, producing five functional 14F7 scFv variants adapted to a 
prokaryote expression system by use of phage display. The clones contained the original 
heavy chain, but different light chains, all with retained specificity and affinity towards the 
NeuGc GM3 ganglioside (Rojas et al., 2004). 
14F7 Structure 
14F7 is a highly mutated antibody produced by an mature humoral response (Vázquez et al., 
1995). The majority of amino acid replacements are located in the VH region, suggesting that 
somatic mutation has occurred separately for VH and VL (David and Zouali, 1995). The VL 
gene is a member of the J558 family. The VLκ belongs to the Vκ23 family and is encoded by 
gene 23-43 (Rodríguez et al., 2007). 
When reporting an antibody structure, the Kabat numbering scheme applies for the CDRs. 
Deletions, insertions and mutations may introduce an unpredictable number of amino acids in 
these areas, making it difficult to compare two antibody sequences. The solution is to give the 
amino acids within the CDRs an alphabetic abbreviation. The CDR H3 in 14F7 can be used as 
an example. The amino acid sequence is N’-Arg98-Leu99-Arg100-Arg100A-Gly100B-
Ile100C-Tyr100D-Tyr100E-Tyr100F-Ala100G-Met100H-Asp101-Tyr102-C’. By always 
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ending the CDR H3 on number 102, the rest of the molecule is still in frame with other 
antibodies. 
Krengel et al. solved the Fab structure in 2004 by X-ray crystallography to 2.5 Å, see Figure 4 
(Krengel et al., 2004). The crystal structure was similar to other reported Fab structures with 
the exception of the CDR 3, of the heavy chain (CDR H3). The binding site was divided into 
two separated zones by an exceptionally long CDR H3 loop, consisting of 16 amino acid 
residues. The unusually long CDR H3 segment arose from the fusion of two D minigenes 
originating from the DSP2 family, giving the segment extra length (Rodríguez et al., 2007). 
These types of long loops are generally thought to be very flexible, but in the crystal, it was 
quite rigid. The rigidity is probably partly due to crystallographic stabilisation within the 
crystal, but a cluster of three tyrosine residues located at the base of the CDR H3 loop 
(Tyr100D, Tyr100E and Tyr100F) may provide extra stabilisation by interacting with other 
aromatic residues, giving the CDR H3 loop more rigidity than what is normally observed 
(Krengel et al., 2004). 
By functionally mapping the paratope of 14F7, using tolerated/not-tolerated mutation analysis 
the results indicate that Trp33 and Tyr100D plays a critical role in recognising the NeuGc 
GM3 ganglioside (Rojas et al., 2012). Even though Trp33 and Tyr100D are completely buried 
within the structure, they could only be exchanged with other aromatic amino acid residues to 
preserve NeuGc GM3 ganglioside binding during the tolerated/not-tolerated mutation 
analysis. Thus confirming aromatic stacking of amino acid side chains as an important 
contributor for the stabilisation of the paratope structure (Rojas et al., 2012). The strongest 
interaction within the CDR H3 loop of the Fab crystal involved three arginine side chains 
(Arg98, Arg100, and Arg100A) (Krengel et al., 2004). In the mutation analysis, Arg100 and 
Arg100A were relatively conserved, while Arg98 was highly conserved. Two of the arginines 
(Arg98, Arg100A) are located in the top part of the CDR H3 loop, creating a small 
hydrophilic groove, together with amino acids from CDR H1, H2 and one amino acid from 
the light chain (Trp94) (Rojas et al., 2012).  
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Figure 4: 14F7 Fab structure solved by Krengel et al. (Krengel et al., 2004). The structure is visualised using 
PyMOL (Schrödinger), PDB code 1RIH. VL is coloured teal green, VH is in violet, and the CDRs are grey. The 
prominent CDR in the middle of the binding site is CDR H3. 
14F7 binding model 
To simulate the ganglioside binding, Krengel et al. proposed a theoretical model of the 14F7-
NeuGc GM3 ganglioside complex (Krengel et al., 2004). Since it was possible to exchange 
the VL without losing affinity for the NeuGc GM3 ganglioside, it was assumed that the 
ganglioside primarily interacted with VH (Rojas et al., 2004). That is why the terminus 
disaccharide moiety of NeuGc GM3 (NeuGcα3Galβ) was docked exclusively at the VH part 
of the structural model. After docking the disaccharide onto the VH, the third carbohydrate 
residue (4Glcβ1) was added. There were no major differences between the reported structure 
and the docking model. It was later discovered by functionally mapping the paratope of 14F7 
that the model is at least partly wrong. Residues (VH: Asp52, Trp33 and Tyr50) identified by 
the docking model as important for recognising the hydroxyl group of the N-glycolyl moiety 
of the sialic acid was in reality not essential for the affinity (Rojas et al., 2012, Krengel et al., 
2004). Since it is this hydroxyl group that separate NeuAc from NeuGc the amino acids 
recognising this specific hydroxyl group of NeuGc GM3, must be vital for the affinity, 
therefore it is clear that the ganglioside is docked incorrectly.  
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1.4 Method-related theory 
1.4.1 Recombinant antibody expression 
Immunotherapy it is common to produce functional antibodies in non-human organisms, as 
for example mice. To be able to treat humans with such antibodies, the murine antibodies 
must be humanised to escape allergic reactions, hypersensitivity and to escape the quenching 
of a therapeutic effect by human anti-mouse antibodies (HAMA). In order to avoid the cross-
species reactivity problem two significant innovations emerged early in the antibody therapy 
field. The ability to make chimeric antibodies by domain grafting the variable domains onto 
human heavy chains reduced the xenogeneic sequence proportion to only about 25% of the 
complete Ab drug. CDR grafting further reduced the xenogeneic sequence proportion to less 
than 10% of the complete Ab drug. Thus, a significant reduction in anti-drug responses was 
achieved, making therapeutic Abs a viable intervention option for sustained treatment 
regimens (Kashmiri et al., 2005). 
Antibodies can be isolated from living organisms such as mice, but these can also be 
produced in vitro. For producing antibodies in vitro, the antibody-producing B cells must be 
immortal. A normal cell will only go through a limited number of cell divisions before the 
cell dies. To make an immortal murine B lymphocyte, the antibody-producing B cell must be 
fused with a cancerous cell, e.g. from the myeloma cell line producing a murine hybridoma 
(Kohler and Milstein, 1975). However, there are limitations connected to human antibody 
production. Generating fully human hybridomas are problematic.  
To overcome this challenge, B cells for hybridoma production are isolated from transgenic 
mice with gene repertoire consisting of human variable domains and murine constant domains 
producing chimeric antibodies (Brüggemann et al., 1989). If successful in producing a 
chimeric antibody, a HAMA response might still take place. However, it can be taken a step 
further, creating a human antibody consisting of murine CDRs. This humanised antibody will 
have a better chance in avoiding depletion due to anti-drug responses. 
Since the Fc region of natural-occurring human antibodies are glycosylated, the therapeutic 
full-size antibodies are usually expressed in mammalian cells where glycosylation is a part of 
the eukaryotic posttranslational modification system (Schaefer and Plückthun, 2012). Fab or 
scFv, on the other hand, are generally not glycosylated and can therefore readily be expressed 
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in prokaryotic cells, for example in E. coli (Schirrmann, 2008). Their small size improves 
tissue penetration for therapeutic application such as in solid cancer therapy, and provides an 
excellent opportunity to study the structure of the antibody paratope (Batra et al., 2002, 
Yokota et al., 1992).  
1.4.2  Prokaryote expression of recombinant scFvs 
The increased demand for scFvs with regard to quality, stability and amount resulted in the 
development of a variety of recombinant production methods, vector systems and expression 
strategies (Schirrmann, 2008).The first functional antibody fragment was produced in E. coli 
in 1988 (Skerra, 1988). Today, there are two main strategies to obtain scFv constructs from 
E. coli. One includes producing the fragments as cytosol inclusion bodies followed by in vitro 
refolding. The disadvantage of this method is that the disulphide bridges can form incorrectly 
without an in vivo folding system (Buchner J., 1992). The other alternative is to utilise the 
secretion machinery of prokaryotic cells. The reducing environment inside the cytosol of a 
bacterium greatly sabotages scFv folding, as the conserved disulphide bonds can only form 
under oxidative conditions (Gilbert, 1990). The disulphide bridges are so important for the 
stability that only intrinsically very stable scFv constructs are able to fold in the cytosol 
(Glockshuber, 1992). With the addition of a signal sequence, construction can be directed to 
the oxidising environment of the periplasm, where the scFv can be isolated in a correctly 
folded state (Pugsley, 1993, Glockshuber, 1990). The main obstacle for high yield production 
in a periplasmic expression system is the formation of insoluble aggregates over correctly 
folded protein, as a consequence of high protein concentration in the periplasmic space 
(Kipriyanov et al., 1997). But by expressing scFv constructs utilising the secretory pathway of 
E. coli, protein can leak out into the medium, resulting in lower host toxicity, and provide the 
opportunity for protein isolation directly from the medium (Takkinen et al., 1991). 
In E. coli, the energetic barrier for RNA polymerase to associate with the promoter is much 
lower compared to eukaryotic cells. Consequently, most promoters in E. coli are regulated by 
a repressor. By coupling scFv expression to a repressor-regulated promoter, the scFv gene is 
not transcribed without repressor dissociation. This prevents the E. coli secretory pathway 
from being overloaded with a foreign molecule. Another technique to improve scFv folding is 
the introduction of periplasmic chaperones, which help to decrease the amount of aggregation 
inside the cells.  
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Periplasmic expression 
It has been discovered that the amount of scFv aggregates depends on the primary sequence 
of the variable domain, being directly responsible for successful folding (Knappik and 
Plückthun, 1995). When using a periplasmic expression system, Kipriyanov et al. found large 
amounts of insoluble scFv aggregate in the spheroplasts pellet (cells that have had their cell 
wall removed) (Kipriyanov et al., 1997). The amount of aggregates could be decreased if the 
incubation was done in test tubes, increasing the periplasm yield. Incubation in Erlenmeyer 
flasks also increased the yield, but caused a higher release of scFv into the medium, which 
could be decreased by expression at lower temperatures. In order to utilise the secretion 
machinery of prokaryotic cells, a signal sequence must be added to the construct. A common 
method is to add a pelB signal sequence at the amino-terminus (N-terminus) end of the 
constructs. This will make the scFv products translocate across the inner membrane of E. coli, 
through the secB-dependent pathway, into the oxidising environment of the periplasm, where 
disulphide bridges can readily form (Sapriel et al., 2002). Another advantage with the secB 
pathway is that binding of preproteins to SecB enables them to exist in a translocation 
competent state that will neither aggregate nor fold (Hardy et al., 1993).  
The periplasmic expression system used to express the 14F7 scFv construct in this thesis was 
developed in E. coli XL1-Blue cells, and the pFKPEN vector was developed especially for 
this system (Gunnarsen et al., 2010, Løset et al., 2007). The vector contains the recombinant 
protein controlled by the lac promoter and constitutively expresses the recombinant FkpA, 
peptidyl-prolyl isomerases, from its native promoter xPO (Gunnarsen et al., 2010, Løset et al., 
2007). 
Chaperone assisted scFv expression 
Chaperones are known to improve expression yield by facilitating folding, reducing protein 
degradation and preventing aggregation (Ramm and Plückthun, 2000, Ying et al., 2004). The 
periplasmic peptidyl-propyl cis-trans isomerase FkpA is found naturally in E. coli and has a 
beneficial effect on scFv expression (Ramm and Plückthun, 2000, Ramm and Plückthun, 
2001, Bothmann and Plückthun, 2000). By co-expressing FkpA together with the scFv 
protein, the degree of scFv proteins trapped in the cytosol decreases, instead protein 
accumulates in the periplasm and a positive growth rate is observed (Gunnarsen et al., 2010). 
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scFv controlled by the lac promoter 
14F7 scFv expression is regulated by the lac promoter. When glucose is present, the 
lac repressor will be bound to the lac operator, a 24-nucleotide sequence located just 
downstream of the lac promoter (Gilbert, 1973). The repressor prevents the RNA polymerase 
to transcribe the lac promoter-regulated genes, giving E. coli a chance to grow without 
experiencing any potential toxic effect. However, since the lac repressor is leaky, a low level 
of the scFv will probably be expressed at all times. The lac repressor disassociates in the 
presence of lactose. Lactose is transformed into its isomer allolactose in the cell. Allolactose 
is the inducer of the lac promoter: it associates with the lac repressor, which in turn 
dissociates from the DNA, making the promoter available for transcription. Artificial inducers 
have also been synthesised, with IPTG (Isopropyl β-D-1-thiogalactopyranoside) being the 
most common for the lac promoter. E. coli prefers glucose over lactose as an energy source, 
which is why the lac promoter will be downregulated in the presence of a mixture between 
glucose and lactose. In order to have effective transcription of the genes controlled by the 
lac promoter must not only the lac repressor be removed by inducer-association but a co-
activator is needed. In the presence of glucose is the co-activator, the cAMP receptor protein 
(CAP) associated with its own repressor inactivating. When glucose is removed it can 
associate with the DNA upstream of the promoter. CAP bends the DNA in a conformation 
that aids RNA polymerase to associate with the Pribnow-Schaller box (TATAAT) upstream 
of the promoter (Gaston et al., 1990). Kipriyanov et al. (1997) reported that a reduction in the 
IPTG concentration and the addition of sucrose to the growth medium just before induction of 
the lac promoter, significantly increased the yield of secreted soluble scFv (Kipriyanov et al., 
1997). They hypothesised that this was due to an increase in the osmotic pressure, resulting in 
an enlarging of the periplasmic space based on the findings of Kiefhaber (Kiefhaber, 1991). 
The positive effect of reducing the IPTG concentration was confirmed by Gunnarsen et al. 
who removed IPTG completely (Gunnarsen et al., 2010). The addition of sucrose to increase 
the protein concentration was also thoroughly investigated indicating that sucrose addition did 
not affect the yield (Gunnarsen et al., 2010).  
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2 Aims of the thesis 
To date it has not been possible to structurally characterise the ligand complex of 14F7 with 
its tumour antigen the NeuGc GM3 ganglioside, mainly because of difficulties reproducing 
the 14F7 Fab crystal. In this thesis, the aim was to generate recombinant single-chain Fv of 
14F7 and express those for binding analysis and crystallographic studies. We generated scFv 
constructs, consisting of the two variable antibody domains connected with a linker peptide. 
Restriction sites flanked the construct and the linker region, making it possible to switch 
between the two different linker regions and the two variable light chain (VL) domains, to 
construct four scFv versions of 14F7. Proteins were expressed in E. coli using a periplasmic 
expression system. Once the proteins were successfully expressed and purified, we attempted 
co-crystallisation with a hydrophilic synthetically derivative of the NeuGc GM3 ganglioside, 
named Tricer. We conducted complementary investigations using ELISA, SPR and 
ThermoFluor and screened for crystals. The experimental part of the thesis can be subdivided 
into three sections as follows: 
1. Cloning, expressing and purifying the scFv constructs 
Design expression constructs of recombinant scFv 14F7, clone the constructs, express and 
purify sufficient amounts of scFv for further analysis. 
2. Binding analysis of scFv and the NeuGc GM3 ganglioside 
Evaluate the affinity between the different scFvs and its tumour antigen using ELISA, SPR, 
and ThermoFluor. 
3. Crystallisation 
Screen for crystallisation conditions of scFv - Tricer complexes, as a first step towards 
obtaining diffraction data and determine the 3D structure by X-ray crystallography.  
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3 Materials & procedures 
All materials and chemicals are listed in the Appendix, Section A: Materials, page S1.  
All solution recipes can be found in the Appendix, Section B: Solutions, buffers and gels, 
page S9. 
All digestion, ligation, PCR primers and corresponding programs are listed in the Appendix, 
Section C: Restriction- and ligation reagents, page S13, and Section D: PCR mixtures and 
PCR programs, page S23. 
All nucleic acid and amino acid sequences are listed in the Appendix, Section E: Nucleic acid 
sequences, page S24 and Section F: Amino acid sequences, page S29. 
3.1 Cloning 
3.1.1 Preparing the scFv constructs 
The sequences (VH-LR-VL.A and LC-VL) were codon-optimised for E. coli expression and 
ordered as synthetic genes (Life technology). A sketch of the constructs is given in 
Section 4.1.1, Figure 9. The scFv constructs were generated by combining the original 
variable heavy chain (VH) with two different murine variable light chains, both from the κ 
family. The two light chains were either the original 14F7 (VL) or an alternative variable light 
chain adapted for prokaryote expression systems (VL.A) (Rojas et al., 2004). The VH is flanked 
by the restriction sites NcoI and HindIII (5’-NcoI-VH-HindIII-3’), while VL/VL.A is flanked by 
MluI and NotI (5’-MluI-VL/VL.A-NotI-3’). To make the scFv constructs, VH-VL and VH-VL.A 
were combined with two different synthetic linkers. One linker, called the original Cuba 
linker (LC.o), originates from Gertrudis Rojas, Centre of Molecular Immunology, Havana, 
Cuba (Rojas et al., 2004). It was elongated by introducing restriction sites flanking the 
sequence (5’-HindIII-LC-MluI-3’), the new version of the linker was named LC. The sequence 
for the second linker, called Rikshospital-linker (LR), was provided by Geir Åge Løset 
(Centre for Immune Regulation and Department of Biosciences, University of Oslo, Norway) 
and already contained the selected restriction sites. The four resulting constructs were named 
Construct 1, 2, 3 and 4 (C1, C2, C3 and C4). The constructs also contain a 6x 
Polyhistidine-tag (His-tag), a TEVp recognition site at the N-terminus and a stop codon at 
20 
their C-terminus. The soluble expression vector pFKPEN, containing an ampicillin resistance 
gene and the FkpA gene regulated by its native promoter xPO, was a kind gift from Geir Åge 
Løset (Gunnarsen et al., 2010). The vector also contains a lac promoter, a Shine-Dalgarno 
sequence and the pelB sequence encoding stretch of the pSEX81 (GenBank accession no. 
Y14584), upstream of the multiple cloning site containing the NcoI and NotI restriction sites. 
Subcloning Construct 1 DIGESTION 
The vector pFKPEN from Geir Åge Løset (Centre for Immune Regulation and Department of 
Biosciences, University of Oslo, Norway) and the VH-LR-VL.A DNA sequence (Life 
technology) corresponding to C1 were digested with NcoI/NotI restriction enzymes (NEB) for 
1.5 hour at 37 °C. The DNA was run on a 1% agarose (Lonza) gel at 90 V for 45 minutes 
together with the two standards ΦX174 (NEB) and λHindIII (Fermentas) and controls where 
the two DNA sequences were mixed with only one restriction enzyme. The resulting vector 
NotI
5’-pFKPEN-3’NcoI and insert NcoI5’-VH-LR-VL.A-3’
NotI
 were extracted from the gel using the 
QIAquick gel extraction kit (QIAGEN). In the last DNA purifying step, 30 µl of the elution 
buffer was used instead of 50 µl to get a higher end concentration. This procedure was 
initiated every time the gel extraction protocol was used. Concentration was measured at 260 
nm using a spectrophotometer (Nanodrop 2000c, Thermo scientific). 
Subcloning Construct 1  LIGATION 
Standard protocol: For calculating the correct amount of insert vs. vector for the ligation, the 
following equations were used with a molar ratio of 4:1. 
( )         
                     
         
 
                  
                  
           
( )                             
         
            
                                   
It is recommended to have around 10-100 ng vector. 60 ng of the vector was mixed with the 
calculated amount of insert and incubated over night with T4 polynucleotide DNA ligase 
(NEB) and T4 ligase buffer at room temperature. Isolated vector without insert was used as a 
negative control.  
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Subcloning Construct 1  TRANSFORMATION 
Standard protocol: Half of the ligation mix was mixed with 300 µl CaCl2 competent XL1 
Blue E. coli cells (recA1 endA1 gyrA96 thi-1 hsdR17 supE44 relA1 lac [F’ proAB 
lacIqZDM15 Tn10 (Tetr)] (Stratagene) and left on ice for 45 minutes. After 3 minutes heat 
shock at 42 °C (Dri-Bloc, Techne), were the cells again put on ice, and 1 ml LB medium was 
added to each eppendorf-tube. The samples were placed at 37 °C for 30 minutes to give the 
vector a chance to express antibiotic resistance. The samples were thereafter centrifuged for 
4 minutes at 4000 × g (Biofuge Fresco Heraeus, Thermo Scientific). ~1.2 ml of the 
supernatant was removed and the remaining ~100 µl was resuspended and plated on 
ampicillin containing agar plates overnight at 37 °C. 
Two colonies from the transformation were incubated overnight in 6 ml 1x LB containing 
100 mg/l ampicillin (AppliChem) and 0.1 M glucose (Sigma) (LB-AG) at 225 rpm (Multitron 
II, Infors). Vector DNA was isolated using the QIAprep spin Miniprep kit (QIAGEN); the 
resulting DNA concentration was measured at 260 nm (Nanodrop 2000c, Thermo scientific). 
The sample was split into three. One part was run on an agarose gel for size control, another 
was used for sequencing and the remaining part was used to make the other scFv 14F7 
constructs. The rest of the bacteria’ cultures was used to make glycerol stocks (20% glycerol, 
Prolabo) and stored at -80 °C. 
Sequencing 
Standard protocol: The constructs were validated by sequencing: 200 ng DNA mixed 
separately with either the forward primer pQE-FP (5’-CGGATAACAATTTCACACAG-3’) 
(Metabion) or the revers primer pHogb (5’-CTAGATTAGTGATGGTGATG-3’) (Metabion). 
The primer sequences correspond to the vectors’ 5’ and 3’ sequences flanking the antibody 
fragment. The primers were used at a concentration of 0.5 µM, and the samples were sent for 
sequencing at the ABI lab, Department of Biosciences, UiO, Oslo. 
Cloning Construct 2 
The pFKPEN containing C1 and the ordered DNA fragment LC-VL (Life Technology) were 
digested for 1.5 hours at 37 °C with NotI/MluI restriction enzymes (NEB). CIP (NEB) was 
also added to the C1-containing vector to prevent re-ligation. As a control, the pFKPEN 
containing C1 was digested separately with NotI or MluI (NEB). The DNA was run on a 1.2% 
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agarose gel at 90 V for 45 minutes together with the two standards ΦX174 (NEB) and 
λHindIII (Fermentas). The (MluI5’-VL-3’
NotI
) insert fragment and the (
NotI
5’-pFKPEN-VH-LR-
3’MluI) vector fragment were extracted from the gel using the QIAquick gel extraction kit 
(QIAGEN). Concentrations were measured using a spectrophotometer (Nanodrop 2000c, 
Thermo scientific) at 260 nm. Ligation and transformation were done following the standard 
protocols. 
Two colonies from the transformation plate were incubated overnight with 6 ml LB-AG at 
37 °C at 225 rpm (Multitron II, Infors). Vector DNA was isolated using the QIAprep spin 
Miniprep kit (QIAGEN). The isolated vector was used for sequencing and a sample fraction 
was run on a 1% agarose gel for size control. The remaining bacterial culture was used to 
make glycerol (Prolabo) stocks and stored at -80 °C. 
Cloning Construct 4 
The pFKPEN containing C1 and the ordered DNA fragment LC-VL (Life Technology) were 
digested with HindIII/NotI restriction enzymes (NEB) at 37 °C (Dri-Bloc, Techne) of 1.5 
hours. CIP (NEB) was also added to the C1-containing vector to prevent re-ligation. As a 
control, pFKPEN containing scFv C1 was digested separately with HindIII or NotI (NEB). 
The DNA samples were run on a 1.2% agarose gel at 90 V for 45 minutes. The (
HindIII5’- LC-
VL-3’
NotI
) insert and the (
NotI
5’-pFKPEN-VH-3’
HindIII
) vector fragments were isolated from the 
gel using the QIAquick gel extraction kit (QIAGEN). Concentrations were measured using a 
spectrophotometer (Nanodrop 2000c, Thermo scientific) at 260 nm and ligation and 
transformation were done following the standard protocols. 
Two colonies from the transformation plate were incubated overnight with 6 ml LB-AG at 
37 °C at 225 rpm (Multitron II, Infors). Vector DNA was isolated using the QIAprep spin 
Miniprep kit (QIAGEN). The isolated vector was used for sequencing and one sample 
fraction was run on a 1% agarose gel for size control. The C4-containing vector was also used 
to make construct C3. The remaining bacterial culture was used to make glycerol (Prolabo) 
stocks and stored at -80 °C.  
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Cloning Construct 3 
The pFKPEN vectors containing C1 and C4 were digested with NotI/MluI restriction enzymes 
(NEB) for 1.5 hour at 37 °C with controls. Digested C4-containing vector was run on a 1% 
agarose gel while digested C1 containing vector was run on a 1.2% agarose gel. The resulting 
vector fragment from C4 (
NotI5’-PFKPEN-VH-LC-3’
MluI
) and insert fragment from C1 (
MluI
5’-
VL.A-3’
 NotI
)
 
were isolated from the gel using QIAquick gel extraction kit (QIAGEN). The 
concentrations were measured at 260 nm using the spectrophotometer (Nanodrop 2000c, 
Thermo scientific). Insert and vector were mixed in a 4:1 ratio using equations (1) and (2). 
Ligation mix and controls were made following standard protocol and transformed into XL1 
Blue competent cells using standard technique. 
Two colonies from the transformation plate were incubated overnight with 6 ml LB-AG at 
37 °C at 225 rpm (Multitron II, Infors). Vector DNA was isolated using the QIAprep spin 
Miniprep kit (QIAGEN). The isolated vector was used for sequencing and a sample fraction 
was run on a 1% agarose gel for size control. The remaining bacterial culture was used to 
make glycerol (Prolabo) stocks and stored at -80°C. 
3.1.2 Oligonucleotide-directed mutagenesis  
Optimised protocol: PCR mediated oligonucleotide-directed mutagenesis was performed for 
removal of the His-tag and the TEVp recognition site. The forward primer was designed 
including the Pribnow box, and the 5’-end NcoI tag and 20 nucleotides of the VH region, 
excluding the 33 nucleotides of the His-tag and the TEVp cleavage site. 20 
nucleotides of the VH region were added to the forward primer (5’-ATATCCATGGCCCAGG
TGCAGCTGCAGCAG-3’) (Eurofins Genomics). The reverse primer contained the 3’-end 
NotI and 20 eversed nucleotides of the VL region (5’-TATAGCGGCCGCTTATTTCAGTTC
CAGTTTGG-3’) (Eurofins Genomics). 
The vectors were subjected to PCR using Phusion DNA Polymerase (Thermo Scientific), one 
of the most accurate thermostable polymerases available today. The resulting DNA fragments 
were run on a 1% agarose gel at 90 V for 50 minutes and purified using a PCR Purification 
Kit (250) (QIAGEN). 1000 ng DNA per scFv construct and 2000 ng of the original plasmid 
pFKPEN were digested with NcoI/NotI restriction enzymes (NEB). The original vector 
pFKPEN was also mixed separately with NcoI or NotI restriction enzymes (NEB) as controls. 
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All samples were incubated at 37 °C for 1.5 hours together with a mix of 1 kbp and 100 bp 
ladders (NEB). The DNA was separated according to size on a 1% agarose gel at 90 V for 
50 minutes before the relevant bands were isolated and purified using the QIAquick gel 
extraction kit (QIAGEN). As for the initial cloning protocol, 30 µl of the elution buffer was 
used during the last step of the extraction instead of 50 µl to get a higher concentration of 
purified DNA. For calculating the correct amount of insert vs. vector for the ligation, 
equations (1) and (2) were used with a molar ratio of 4:1. 
Ligation and transformation were performed according to standard protocol. Glycerol stocks 
(20% glycerol, Prolabo) were made from two colonies per construct. Transformed plasmids 
were purified using the miniprep Nucleo Spin Plasmid kit (Macherey-Nagel GmbH & Co. 
KG) and sent to sequencing. Sequencing was performed using the standard protocol. The new 
constructs were named 14F7 scFv: C1*, C2*, C3* and C4*. 
3.2 Expression protocols 
3.2.1 Growth conditions  
Transformed XL1-Blue E. coli cells (Stratagene) were grown over night in 100 ml 2x YT 
medium with 100 mg/l ampicillin (AppliChem) and 20% glucose (Sigma) (2x YT-AG) at 
125 rpm, 37 °C (Multitron II, Infors). The next day the main cultures were inoculated to 
OD600 of 0.025 in 1 L 2x YT-AG in 2 litre Erlenmeyer flasks and incubated at 125 rpm, 37 °C 
(Multitron II, Infors) until the OD600 reached 0.6-0.8. The bacteria were pelleted by 
centrifugation (4000 × g, 40 min, 4 °C) (Centrifuge 5810 R, Eppendorf) and resuspended in 
an equal volume of fresh 2x YT medium containing 100 mg/ml ampicillin (AppliChem) (YT-
A). The cultures were left overnight at 125 rpm, 30 °C (Multitron II, Infors). 
3.2.2 Isolation of soluble periplasmic proteins 
Standard protocol 
If the OD600 was close to or over 1 for the overnight cultures, the cells were harvested by 
centrifugation (4000 × g, 40 min, 4 °C) (Avanti centrifuge J-26 XP, Beckman Coulter). The 
pellets were resuspended in ice-cold periplasmic extraction buffer with 80 µg/ml lysozyme 
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(Sigma) and 80 µg/ml RNase A (Sigma), and incubated for 1 hour at 4 °C with shaking 
(Multitron II, Infors). The samples were centrifuged (4000 × g, 40 min, 4 °C (Centrifuge 5810 
R, Eppendorf), giving the soluble periplasmic extracts as the supernatants, and spheroplasts 
with insoluble periplasmic material as the pellets. The supernatants were filtered through 
0.2 µm filter (Rapid Flow, Nalgene) into clean glass bottles and stored at 4 C. If the storage 
periods exceeded one week, the soluble periplasmic extracts were frozen to -80 °C. 
Cracking the cells using high-pressure homogeniser 
If the OD600 was close to or over 1 for the overnight cultures, the cells were harvested by 
centrifugation (4000 × g, 40 min, 4 °C) (Avanti centrifuge J-26 XP, Beckman Coulter). The 
pellets were resuspended in cell cracking buffer, 5-10 ml buffer per 1 g wet pellet. The cells 
went through two rounds of homogenisation using the high pressure homogeniser 
(EmulsiFlex-C3, Avestin). The cell lysate was centrifuged at 48000 × g for 20 minutes at 4 °C 
(Centrifuge 5810 R, Eppendorf). The supernatants were filtered through 0.2 µm filter (Rapid 
Flow, Nalgene) into clean glass bottles and stored at 4 C. 
3.3 Protein purification 
3.3.1 Affinity chromatography 
Immobilised metal affinity chromatography (IMAC) 
The soluble periplasmic extract was adjusted to a buffer composition similar to the binding 
buffer used in IMAC (Immobilised metal affinity chromatography) (see buffer compositions 
in the Appendix, Section B: Solutions, buffers and gels, page S1). IMAC was performed at 
4 °C using a 5 ml column of chelating Sepharose (GE Healthcare) charged with Ni
+2
, on the 
ÄKTApurifier-900 (Biosciences, GE Healthcare). The column was equilibrated with a 
binding buffer with pH 7.8. The sample was loaded onto the column and washed with 4 
column volumes of binding buffer. The bound proteins were eluted with a gradient of 0-100% 
of elution buffer with pH 7.8, over 6 column volumes. Fractions of 1 ml were collected 
throughout the procedure and absorbance was recorded at 254 and 280 nm and analysed using 
the Unicorn 5.11, GE Healthcare software. SDS-PAGE was performed according to standard 
procedure, see Section 3.4.2, page S27. IMAC fractions with proteins of the correct size 
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(~30 kDa) were pooled, concentrated and dialysed against 50 mM Tris-HCl (Chalbiocem) at 
pH 7.5 (Amicon ultra filter, Ultracell-10 K, 15 ml and 2 ml, Millipore). The concentration 
was measured (A280nm, NanoPhotometer, IMPLEN) and the sample stored at -80 °C. The 
column was washed with binding buffer and water, and stored in 20% ethanol (Arcus) at 4 °C. 
Protein L affinity chromatography 
Soluble periplasmic extract was adjusted to a buffer composition similar to the binding buffer 
used in Protein L affinity chromatography (buffer compositions in the Appendix, Section B: 
Solutions, buffers and gels, page S9). Affinity chromatography was performed using gravity 
columns containing 1 ml of Protein L capto resin (GE healthcare). A separate column was 
used for each construct. The columns were equilibrated with binding buffer. The samples 
were loaded onto the columns and washed with 20 ml of binding buffer pH 7.8. The proteins 
were eluted with elution buffer of pH 3 and neutralised to pH 7.8 with 50 mM Tris-HCl 
(Chalbiocem). SDS-PAGE was performed according to standard protocol (see Section 3.4.2, 
page 27), and fractions with proteins of the correct size (~28 kDa) were pooled and 
concentrated (Amicon ultra filter, Ultracell-10 K, 15 ml and 2 ml, Millipore) before purified 
further by size-exclusion chromatography (SEC ). The columns were neutralised with 20 ml 
1 M Tris-HCl (Chalbiocem) with pH 9 and stored in 20% ethanol (Arcus) at 4 °C. 
Size-exclusion chromatography (SEC) 
Analytical gel filtration was performed after affinity chromatography using a Superdex 200 
R10/300 (GE healthcare) column installed on the ÄKTApurifier-900 (Biosciences, GE 
Healthcare) with 50 mM Tris-HCl (Chalbiocem) with pH 7.8 as the running buffer. Sample 
volume and flow rate were 500 µl and 0.5 ml/min respectively. Fractions of 0.5 ml were 
collected throughout the procedure and absorbance was recorded at 254 nm and 280 nm 
(Unicorn 5.11, GE Healthcare). SDS-PAGE was performed according to standard procedure 
(see Section 3.4.2. page 27), and SEC fraction with proteins of the correct size (~28 kDa) 
were pooled, concentrated and dialysed against 50 mM Tris-HCl (Chalbiocem) at pH 7.5 
(Amicon ultra filter, Ultracell-10 K, 15 ml and 2 ml, Millipore). The concentration was 
measured (NanoPhotometer, IMPLEN) and the sample stored at -80 °C. 
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3.4 Concentration measurements 
3.4.1 DNA 
The DNA concentrations were measured at 260 nm using a spectrophotometer (Nanodrop 
2000c, Thermo scientific). 
3.4.2 Protein 
The protein concentrations were measured at 280 nm using the NanoPhotometer (IMPLEN). 
Throughout the thesis the protein concentrations were measured incorrectly. When measuring 
the concentration the absorbance coefficient for the specific protein must be inserted in the 
NanoPhotometer program. The NanoPhotometers manual does not specify if it is the direct or 
the inverted absorbance coefficient that should be used. It was therefore assumed that the 
direct coefficient could be inserted. But, just before finishing the thesis it was discovered that 
the machine requires the inverted coefficient to calculate the correct protein concentration. 
For proteins with a coefficient close to 1, this would not give noteworthy errors. However, 
since the scFvs has an absorbance coefficient (Abs280nm) of ~1.87, (see scFv info in Table 4) 
the change in reported protein concentration is significant, as the inverted number is 0.535. 
By measuring scFv concentrations with the inverted coefficient it was discovered that earlier 
measurements overestimated the concentrations by a factor of ~3.2. 
3.5 Electrophoresis 
3.5.1 Agarose gel 
The agarose concentration in the gel is directly correlated to the pore size, controlling DNA 
migration. DNA migrates towards the anode due to its negative charge. Linear double 
stranded DNA migrates with a velocity that is inversely proportional to the logarithm of the 
number of base pairs. In practice, this means that small DNA molecules migrate faster 
through the gel than larger molecules. Circular molecules on the other hand do not follow the 
same rule. Circular DNA molecules can be packed densely due to supercoiling, making them 
move faster through the gel than their linear counterpart. To visualise the DNA, a DNA-
binding compound is added to the gel that fluoresces when exposed to ultraviolet light. As the 
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DNA moves through the gel, it will bind the fluorescent compound. The strength of the 
accumulated fluorescent signal reflects the DNA concentration. 
Standard procedure: Agarose (Lonza) was mixed during heating with 1xTAE buffer to a final 
agarose concentration of 1% or 1.2%, depending on the DNA fragment size. The agarose 
solution was stored at 37 °C. When casting a gel, 50 ml agarose solution was mixed with 5 µl 
SYBR safe DNA stain (Invitrogen), to visualise the DNA bands through fluorescence. The 
gel was set after 20 minutes (Mini Horizontal Submarine Unit), 1xTAE buffer was added 
until the gel was completely covered. Then the DNA samples were loaded into the wells using 
ΦX174 (NEB), λHindIII (Fermentas), as molecular weight standards or a mixture of 1kbp 
(NEB), and 100 bp (NEB) molecular weight ladders, to indicate fragment size (see Figure 5 
for molecular weight information) The gels were run at 90 V for 45 minutes (PowerPack HC 
power supply). 
 
Figure 5: From left: ΦX174 standard on a 1.7% agarose gel, λHindIII standard on a 1.0% agarose gel,1 kbp 
ladder on a 0.8% agarose gel, and 100 bp ladder on a 1.2% agarose gel. 
  
29 
 
3.5.2 SDS-PAGE 
Sodium dodecyl sulphate polyacrylamide gel electrophoresis (SDS-PAGE) was used to 
separate proteins according to their respective sizes. Sodium dodecyl sulphate (SDS) is a 
denaturing detergent: it binds to the protein with its hydrophobic part in a 1.4:1 ratio and 
unfolds it giving it a rodlike shape. Its hydrophilic section is negative, masking the proteins’ 
intrinsic charge, giving all proteins the same mass to charge ratio (Voet and Voet, 2011). 
During electrophoresis, the negative charge will make all proteins move towards the anode, 
the migration rate will be determined by the gel’s pore size and the molecular size of the 
proteins. 
Standard procedure: 7.5 µl of each sample were mixed with 4 µl 4x NuPAGE LDS Sample 
buffer (Invitrogen,) and 3.5 µl MQ-H2O. The samples were heated for 10 minutes at 70 °C, 
spun down (using Capsulefuge, TOMY PMC-060, Tomyteck) and loaded on a NuPAGE Bis-
Tris 4-12% gel (Life technology). SeeBlue
®
 Plus2 prestained standard (Invitrogen) was used 
to get an indication of protein size (see Figure 6 for molecular weight information). The gel 
was coupled to an Electrophoresis powersupply-EPS601 (GE healthcare) and run for 
35 minutes at 200 V in 1x MES SDS Running buffer (Invitrogen). 
 
Figure 6: SeeBlue
®
 Plus2 prestained standard (Young-Pearse, 2009) 
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3.5.3 Coomassie staining 
The polyacrylamide gel was stained for one hour in Coomassie staining solution after SDS-
PAGE. The gel was thereafter de-stained with MQ-H2O, until a clear contrast between 
background colour and protein bands was detected. The gel was stored in MQ-H2O until a 
picture was taken. 
3.5.4 Silver staining 
After SDS-PAGE, the polyacrylamide gel was incubated with shaking for 10 or more minutes 
in MQ-H2O water. Thereafter the gel was incubated with shaking in 50 ml fixation mix for 20 
minutes, followed by incubation with 50 ml Farmer’s Reducer for 2 minutes. The gel was 
washed multiple times in MQ-H2O until the yellow colour disappeared. After washing, the gel 
was silver stained with 0.1% 50 ml silver nitrate solution (AgNO3) (Merck) for 15 minutes 
with shaking. The gel was then subjected to two rounds of washing: first 30 seconds with 50 
ml MQ-H2O, followed by 30 seconds with 50 ml 2.5% sodium carbonate (Na2CO3) (Sigma). 
The silver staining was developed by placing the gel in 50 ml developing solution until the 
protein bands were visible. The development was stopped by adding 100 ml of 10% v/v 
acetic acid (Merck). The gel was incubated with shaking for 10 minutes, followed by two 
rounds of washing with 10 ml MQ-H2O. The silver stained gel was stored in MQ-H2O until a 
picture was taken. 
3.6 Analysis by Mass Spectrometry 
Depending on the protein’s mass, m, and its positive or negative charge, z, every protein 
possesses a mass/charge, (m/z) ratio. A powerful magnetic field as used in mass spectroscopy 
(MS) will be able to deflect ionized samples based on this ratio.  
IMAC purified C1 from 13.05.2013, was separated according to size on a NuPAGE Bis-Tris 
4-12% gel (Life technology). The band corresponding to the scFv size (~30 kDa) was excised 
and further analysed by mass spectrometry using the Orbitrap-XL (Thermo Fisher). 
Protein C1*, C3* and C4* -fractions from SEC were run on a NuPAGE Bis-Tris 4-12 % gel 
(Life technology). Bands with the sizes of scFvs (~28 kDa) and the bands corresponding to 
~14 kDa were excised for all three scFvs and sent to MS analysis, where it was compared 
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with the different 14F7 scFv, FkpA and lysozyme sequences. The results were returned and 
analysed using the Scaffold 4 software (Proteomic Software Inc.) 
MS analyses were performed by Bernd Thiede’s group, at The Biotechnology Centre of Oslo. 
3.7 ELISA 
Enzyme-linked immunosorbent assays (ELISA) were used to determine the affinity between 
scFv and its antigen. 
3.7.1 Direct ELISA 
Proteins diluted in 1x PBS to the desired protein concentrations were incubated overnight in 
Nunc-Immuno 96 MicroWell MaxiSorp solid plates (Sigma) wells (see Appendix for solution 
recipes, Section B: Solutions, buffers and gels, page S9). The plates were washed the next day 
with 1x PBS containing 0.1% Tween 20 (Sigma) (PBS-T) and blocked with 1x PSB-T 
containing 5% skimmed milk (AppliChem) (PBS-TM) for one hour at room temperature. The 
binding was developed as described below. Every experiment was duplicated to ensure 
reproducible results. 14F7 mAb (CIM) was included as a positive control and BSA (bovine 
serum albumin) (NEB) was used as a negative control. 
3.7.2 Indirect ELISA 
The Nunc-Immuno 96 MicroWell PolySorp solid plate (Sigma) wells were incubated with 
100 µl NeuGc GM3 ganglioside (10 µg/ml) in methanol (Prolabo) overnight, allowing the 
methanol to evaporate. Plates were washed with 300 µl of PBS-T and blocked with 300 µl 
1x PSB-TM for one hour at room temperature. The scFv constructs were diluted in 1x PBS to 
the desired concentration, and 100 µl solutions were added to the wells and incubated on the 
plate for 1.5 hours at room temperature. The plate was washed with 300 µl PBS-T and 
developed following the standard protocol, described below. Every experiment was done in 
duplicates. 14F7 mAb (CIM) was included as a positive control for NeuGc GM3 ganglioside 
recognition, and BSA (NEB) was used as a negative control.  
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3.7.3 Detecting protein binding in ELISA 
Anti-His-tag antibody  
For scFv containing the His-tag, a murine monoclonal anti-polyhistidine-alkaline phosphatase 
antibody (Sigma) was utilised. It was diluted in 1x PSB to a 1: 2000 compared to the scFv 
concentration before adding 100 µl of solution to each well. The plate was incubated for 
1 hour at room temperature, and washed with PBS-T before the addition of 
p-nitrophenylphosphate substrate (pNPP) (Sigma). The signal was observed by visual 
inspection before and after stopping the reaction with 1 M NaOH (Kebo Lab). Every 
experiment was done in a parallel to ensure a reproducible result. 14F7 mAb (CIMM) was 
included as a positive control for NeuGc GM3 recognition, and BSA (NEB) was used as a 
negative control. Since no micro plate reader was available at our laboratory, the plates were 
frozen at -20 °C for later signal detection. Unfortunately, a side reaction occurs when the 
plates are frozen and the solutions turn brown, making signal detection unreliable. 
Protein L-HRP 
To develop scFvs without His-tag, Protein L coupled to horseradish peroxidase (Genscript) 
(HRP) was utilised (Protein L-HRP). It was diluted with 1x PBS to a 1:1000 ratio compared 
to the scFv concentration, 100 µl was added to the each well and the plate was incubated for 1 
hour at room temperature. The plate was again washed in PBS-T before the addition of the 
substrate TMB (Chalbiocem) solution. The chromatographic development was observed by 
visual inspection. The reaction was stopped by adding 100 µl 1 M HCl. Every experiment was 
duplicated on the same plate to ensure a reproducible result. 14F7 mAb was included as a 
positive control for NeuGc GM3 recognition, and BSA (NEB) was used as a negative control. 
3.8 Western blotting 
3.8.1 Blotting 
Protein separated on a gel (NuPAGE Bis-Tris 4-12% gel, Life technology) by SDS-PAGE 
was placed in transfer buffer for 10 minutes. A piece of Immobilon-P membrane (Millipore) 
corresponding to the size of the gel was dipped in 100% methanol (Prolabo) for 15 seconds, 
then immediately soaked 5 minutes in MQ-H2O, followed by 5 minutes in Transfer buffer. An 
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extra thick paper blot (Bio-Rad Laboratories) was soaked in Transfer buffer and placed on the 
Trans-Blot
®
 SD Semi-Dry Transfer Cell (Bio-Rad Laboratories) apparatus. Then, the wet 
Immobilon-P membrane (Millipore) was placed over the wet paper blot, before a new wet 
paper blot was placed on top. Trapped air was removed and the blotting was run at 25 V for 
30 minutes. 
3.8.2  Immunodetection 
The membrane was incubated in PBS-TM for 1 hour with agitation, followed by 20 seconds 
in new PBS-TM solution. Then the membrane was incubated for 1 hour in PBS-TM 
containing 1:2000 Protein L-HRP (Genscript) with agitation. After the incubation time, the 
membrane was washed twice for 5 minutes in PBS-T and once for 5 minutes in 1x PBS. 
Two different substrates were used to detect scFv:  
1. Insoluble TMB: The membrane was placed in 15 ml insoluble TMB solution 
(Chalbiocem) and incubated for 10 minutes with agitation. The TMB solution was removed 
and the membrane rinsed in MQ-H2O, before it was dried at room temperature and 
photographed. 
2. SuperSignal West Femto Chemiluminescent Substrate was used combined with 
Protein L-HRP to detect scFvs (Thermo Scientific). To detect a signal Amersham Hyperfilm 
ECL (GE healthcare) was used with an X-Ray film developer (Fuji) localised in a dark room. 
3.9 Surface plasmon resonance  
In Surface plasmon resonance (SPR), a CM5 chip (GE Healthcare) was used to detect scFv 
binding. The chip contains 4 channels, but only 2 were used per experiment: one reference 
channel (nr 1) and a binding channel (nr 2). The ganglioside was immobilised in channel nr 2. 
During SPR, the scFv was first run through the reference channel, measuring the background 
binding to the dextran matrix of the chip, followed by the binding channel. Next, the 
background signal was subtracted from the signal, resulting in a graph giving information 
about the molecular interaction kinetics.  
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3.9.1 Immobilising NeuGc GM3 on the CM5 chip 
~0.15 mg Neu GcGM3 was dissolved in 100 µl methanol, then diluted in ethanol (Arcus) in a 
1:9 ratio followed by a second round of dilution in a 1:3 ratio using HBS-N buffer (GE 
Healthcare). The system containing a CM5 (GE Healthcare) chip was washed with HBS-N 
(GE Healthcare) buffer containing 5 µM NaCl (Prolabo) and 0.1% P20 (GE Healthcare) until 
the signal stabilised. The ganglioside solution was run over channel nr 2 at a low speed (5 µl 
per minute for 30 minutes). A reference value of 50 or above indicates a coated chip, if the 
value is below 50 must the chip be re-coated. 
3.9.2  scFv affinity measured by SPR 
Humanised 14F7 mAb (CIM) at the same molar concentration as the mid concentration 
chosen for the scFv samples was run over the chip before and after an experiment, the affinity 
graphs were compared as a control to make sure the signal did not degenerate. All proteins 
were diluted in HPS-EP buffer (GE Healthcare) to the desired concentrations. The mid 
concentration of scFv was always duplicated to check for a reproducible result. The proteins 
were run separately in a single-cycle with the concentration range of 25, 50, 151, 151, 455, 
910 nM (believed at the time to be 81, 162, 486, 486, 1458, 2916 nM, because of a 
misinterpretation in how to measure the protein concentration, see Section 3.4.2, page 27). 
After completing the experiment, Rune Johansen Forstrøm (Engineer at Oslo university 
Hospital, Oslo) performed curve fitting and computer calculations, for kinetic evaluation. 
3.10  ThermoFluor 
After mixing protein and dye in the wells of a 96-well plate, LightCycle 480 (Roche) with 
LightCycle 480 sealing foil (Roche) was used to test the thermal stability. The temperature 
was gradually raised from 20 °C to 90 °C, with steps of 0.3 °C every 3 seconds. The proteins 
eventually unfold due to high temperature, and the dye binds nonspecifically to exposed 
hydrophobic regions, emitting a signal detected by LightCycle 480 using the LightCycle 
software (Roche). The SYPRO Orange (Sigma) dye was used in these experiments, but 
different dyes can be used to optimise the signal. The resulting melting curve will give the 
melting temperature for the protein, which indicates its stability. 
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An initial ThermoFluor experiment was performed where C1, C3 and C4 were screened for 
the optimal scFv/dye concentration ratio. Since C2 was not obtained in high enough amounts, 
it was not included in the experiment. The result indicated that the highest protein 
concentration at 30 µg/ml (believed at the time to be 100 µg/ml, see explanation in Section 
3.4.2, page 27) combined with the middle dye concentration (1:1000 SYPRO, Sigma) were 
the best for further analysis. 
Ligand binding might stabilise the protein structure, giving the proteins increased stability and 
correspondingly a higher melting temperature. Two different antigens were available: NeuGc 
GM3 and a hydrophilic synthetic derivative of NeuGc GM3 called Tricer (see Figure 7). In 
order to investigate scFv stability with and without antigen, the scFv concentration was held 
constant at 30 µg/ml, the dye constant at a 1:1000 ratio, and an increasing concentration of 
either the NeuGc GM3 ganglioside or the Tricer (0 µg/ml, 10 µg/ml, 20 µg/ml, 30 µg/ml) was 
added. The ganglioside had first been solubilised in methanol (Prolabo), before the methanol 
solution was added to the scFv samples. Whit an increased NeuGc GM3 concentration 
followed a correspondent increase in the methanol concentration. The scFvs were diluted to a 
final concentration of 30 µg/ml, with 1:1000 dye, in 50 mM Tris-HCl (Chalbiocem) 
containing 750 mM NaCl. The antigen/scFv mix was incubated for 2 hours before subjecting 
it to ThermoFluor. The result was analysed by Gabriele Cordara, University of Oslo, Oslo, 
with the data software GraphPad Prism v5 (GraphPad software Ink). 
 
 
Figure 7: Molecular composition of the soluble NeuGc GM3 variation named Tricer. Tricer only contains the 
first ethylene group of the ceramide lipid, and was made more hydrophilic by the addition of an acetamide group 
(the ethylene group and the acetamide group are shown in red). 
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3.11 Crystallisation 
C1* scFv in 50 mM TrisHCl was mixed with a soluble derivative of the NeuGc GM3 
ganglioside called Tricer (see Figure 7) in approximately ten times higher molar 
concentration. 
The mixture was incubated for 1 hour before setting up the crystallisation screen using 
Crystallisation Plate, 96 MRC (SWISSCI) plates with vapour diffusion. The screening was 
done with the Oryx4 (Douglas Instruments) robot using the Wasp Run computer program 
(Douglas Instruments), with drops of a final volume of 0.4 µl, consisting of 50% or 25% 
protein solution. The different buffer screens used for crystallisation screening are listed in the 
Appendix, Section A: Materials, Table S7. The plates were stored in the dark at 4 °C and 
checked after 2 weeks, 1 month, 2 month and 4 month, respectively. 
Optimised screening was done with larger drops of 2 µl with either 50% or 25% protein. The 
screening conditions were optimised using Morpheus MDI-46 kit (Molecular dimensions) 
containing all the different reagents. The protein mix was placed on siliconised cover slides 
(Hampton Research) in a hanging drop experiment using TPP
®
 tissue culture plates, 24 wells 
(Sigma). The plates were stored in the dark at 4 °C and checked after 2 weeks, 1 month, 2 
month and 4 month, respectively. 
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4 Results and Discussion 
4.1 Status at project start 
The 14F7 Fab structure was solved by Krengel et al. at a resolution of 2.5 Å (see Figure 4) 
(Krengel et al., 2004). Since it was not possible to reproduce the crystal, the mystery of how 
14F7 binds to the NeuGc GM3 ganglioside is still not solved experimentally. Therefore, we 
wanted to investigate the possibility of crystallising a less complex 14F7 version, the single-
chain Fv (scFv). This thesis is not the first attempt to produce functional 14F7 scFvs. Rojas et 
al. at the Center of Molecular Immunology, Havana, Cuba were not able to express 14F7 scFv 
consisting of the original VH and VL combined with their in-house constructed linker (original 
Cuba linker, LC.o) (Rojas et al., 2004). However, by combining VH with different variable 
light chains, they succeeded in producing five scFvs with conserved antigen affinity, solving 
the expression problem. The clone with the highest NeuGc GM3 affinity was named 3Fm 
(Rojas et al., 2004). 
4.1.1 Synthesising the genes 
We received the sequence for both the original and the 3Fm scFv, and Geir Åge Løset (Centre 
for Immune Regulation and Department of Biosciences, University of Oslo, Norway) 
discovered a truncation of 21 amino acids at the N-terminus of the VH sequences in the 
original 14F7 scFv. It was confirmed by Gertrudis Rojas that the obtained sequence was 
indeed used experimentally for producing the original scFv, and that the truncation probably 
occurred during PCR (G. R. personal communication). This is likely the reason why Rojas et 
al. did not manage to produce the original scFv, as the truncation might have caused stability 
issues. When Geir Åge Løset synthesised the VH gene, the truncation was corrected by 
reconstructing the missing 21 amino acids based on comparison with its V gene germ line 
segment. 
When designing recombinant proteins, tags are practical for purification and detection. 
However, one of the aims of this thesis was to produce crystals, and flexible tags, which 
might disturb crystal formation, should be avoided. To be able to remove such a tag, in this 
case a Polyhistidine-tag (His-tag, 6x), a TEVp recognition site was included in the DNA 
construct. TEVp recognises the amino acid sequence ENLYFQ\S where ‘\’ denotes the 
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position of the cleaved peptide bond. If the His-tag with the TEVp recognition were to be 
placed C-terminally, the six amino acids from the TEVp recognition site would not be 
removed, again resulting in a flexible C-terminus. To avoid this issue, the His-tag combined 
with the TEVp recognition site was placed N-terminally for VH in the scFv. In retrospect, this 
was not well thought through. By looking at the 14F7 structure in PyMOL (Schrödinger) 
(PDB code: 1RIH (Krengel et al., 2004), see Figure 8), the N-terminus of VH is placed next to 
the CDRs. Therefore, an N-terminal His-tag may affect the scFvs affinity towards the NeuGc 
GM3 ganglioside, as discussed in Section 4.2.4 page 46. A synthetic scFv linker normally has 
a length between 15-25 amino acids (Bird, 1988). We hypothesised that the linker used in the 
original scFvs (original Cuba linker, named: LC.o) might have been too short, making it 
difficult for the scFv constructs to fold. Therefore, we added four extra amino acids to the 
linker introducing HindIII/MluI flanking restriction sites, resulting in a 21 amino acid long 
linker (
HindIII5’-LC-3’
MluI
) named LC. In an alternative construct, we used a different linker 
sequence, in order to explore the effect that the amino acid composition may have on the 
scFvs ability to form soluble proteins. The alternative linker was an integrated part of the 
vector system obtained from Geir Åge Løset (Centre for Immune Regulation and Department 
of Biosciences, University of Oslo, Norway) and named LR. After codon optimisation for E. 
coli expression, the synthetic genes were ordered from Life technology and the resulting DNA 
sequences for the four scFvs can be found in the Appendix, Section F: Amino acid sequences, 
page S29.  
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Figure 8: 14F7 Fv structure based on the Fab structure solved by Krengel et al. by X-ray crystallography, PDB 
ID: 1RIH (Krengel et al., 2004). The VH chain is coloured violet, while the VL chain is coloured teal green, the 
CDRs in grey, the N-terminal position of VH is highlighted and the β-sheets are shown as arrows. 
4.2 scFv constructs containing a His-tag 
4.2.1  Cloning, subcloning and transformation 
By generating four scFv constructs, we hoped to increase the chance for success both with 
respect to the yield and antigen affinity. The four resulting constructs (see Figure 9) were 
successfully cloned into the pFKPEN vector (see Figure 10) and transformed into E. coli XL1 
Blue cells (Stratagene). In Figure 11 the finished C1 and C4 scFv constructs was digested 
with NcoI and MluI restriction enzymes for subcloning the C3 scFv. Figure 12 shows two 
clones of the generated C3 scFv that has been isolated from E. coli cultures.  
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Figure 9: Overview, Cloning and subcloning of the 14F7 scFv constructs. To the left: the constructs’ names (C1, 
C2, C3 and C4) followed by a block sketch of the DNA composition. To the right: a domain sketch of the scFvs. 
VH represents the variable heavy chain, VL represents the 14F7 variable light chain, VL.A represents an alternative 
variable light chain, LC represents a modified version of the linker obtained from our collaborators at CIM in 
Cuba, and LR represents the linker obtained from Geir Åge at CIR, Rikshospital. The sketch-designed is inspired 
by Gunnarsen et al. (Gunnarsen et al., 2010). 
 
Figure 10: Overview, C1 subcloned into the pFKPEN vector. From the left: the lac promoter (lacPO), Shine-
Dalgarno sequence (Sd), followed by the scFv construct 1 including the pelB sequence and the His-tag. On the 
opposite strand: The chaperon FkpA with FLAG-tag controlled by its native promoter xPO. The sketch-designed 
is inspired by Gunnarsen et al. (Gunnarsen et al., 2010). 
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Figure 11: Subcloning of C3. C3 was generated from fragments of C1 and C4 already subcloned into pFKPEN. 
C1 and C4 in pFKPEN were both digested with NotI and MluI. VL (size 341 bp) of C1 was isolated from the 
1.2% agarose gel (right), while C4 in pFKPEN (size: 4470 bp) without its VL.A was isolated from a 1% agarose 
gel (left) and used for ligation to generate C3. 
 
Figure 12: Subcloning ofC3. After generating C3 within pFKPEN (4815 bp) and transforming the plasmid in E. 
coli, plasmids from two different E. coli colonies were isolated on a 1% agarose gel. Isolated C4, pFKPEN (4815 
bp) was used as a size control. The isolated plasmids were sent to sequencing and their identities were 
confirmed.  
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4.2.2 Protein expression and isolation I 
The scFv expression is controlled by the lac promoter in E. coli. In order to help the cells 
grow, the scFv expression was downregulated by the addition of 20% glucose until the OD600 
reached ~0.7. Then, the glucose was removed, but no inducer was added. The repressor is 
leaky and will allow for sporadic RNA transcription even without an inducer present, 
resulting in a low expression profile that prevents the formation of insoluble aggregates and 
increases the overall yield (Kipriyanov et al., 1997, Gunnarsen et al., 2010). The next step 
was to incubate the cells at 30 °C overnight without glucose, to give the bacteria time to 
express the proteins.  
After expression and purification sufficient amounts of C1, C3 and C4 were obtained. 
Unfortunately, did not C2 express in high enough amounts for effective isolation. The 
sequencing confirmed that the C2 gene was successfully introduced into the pFKPEN vector, 
and transformed into E. coli. Therefore, the expression issue probably originates in the 
expression protocol In the beginning, we thought that C2 did not express well because the 
original pH of the growth medium (2x YT medium, pH 7.1) was exactly the same as the pI for 
the C2 scFv (information of pI for the different scFvs are listed in Table 1). The growth 
medium’s pH was consequently changed to 7.8 to avoid the destabilising effect, but the 
expression did not improve. Another possibility was that the cell growth peaks earlier for C2 
in the 30 °C overnight culture, than for the other scFvs. If the C2 bacteria started to die during 
the night, the C2 scFv might have been degraded. Although, it would probably be possible to 
optimise C2 expression no further effort was made, since it was possible to obtain sufficient 
amounts of C1, C3, and C4. After expression, isolation, and purification, the average yield for 
the C1 scFv was 5 mg per litre of E. coli culture, while the C3 scFv had a yield of 3 mg, and 
the C4 scFv a yield of 0.3 mg per litre of E. coli culture. 
Rojas et al. did not manage to express scFv containing the original variable light chain in a 
prokaryotic expression system (Rojas et al., 2004). However, from the initial results in this 
thesis, it is confirmed that swapping the variable light chain improves scFv expression 
significantly. In addition to expression scFvs containing VL.A we also managed to express C4, 
a scFv containing the original 14F7 VL. C4 differs from the original 14F7 by the elongated 
linker (4 amino acids), and the corrected truncation of the 21 amino acids at the N-terminus of 
VH. This truncation is probably the main reason for why Rojas et al. did not manage to 
express the original 14F7 scFv (Rojas et al., 2004).  
43 
 
Table 1: scFv protein information calculated based on the amino acid composition using 
ProtParam, ExPASy (Swiss Institute of Bioinformatics) (Artimo et al., 2012).  
 C1 C2 C3 C4 
amino acids 268 268 268 268 
weight (kDa) 30.0 30.0 29.9 29.9 
pI 6.7 7.1 8.2 8.6 
ext. coefficient  
M
-1
 cm
-1
 
54570 55600 54570 55600 
absorption coefficient  1.82 1.86 1.83 1.85 
instability index 
(Below 40 indicate stable 
proteins) 
36.9 49.3 37.5 50.0 
 
4.2.3 Purification using immobilised metal affinity chromatography  
When purifying a protein with chromatography there are several different methods available. 
It is recommended to begin with the most specific technique, as for example affinity 
chromatography. Then, continue with more general separation techniques, as for example 
ion-exchange chromatography (IEC), followed by size-exclusion chromatography (SEC).For 
every purification step a fraction of protein is lost. Therefore, it is advisable to only include as 
many purification steps as is strictly necessary, depending on the degree of purity that is 
required for future experiments. 
The scFv constructs contained a His-tag, giving the opportunity to selectively isolate the 
scFvs by affinity chromatography loaded with nickel ions, this specific affinity 
chromatography technique is named: immobilised metal affinity chromatography (IMAC). 
The absorbance was measured at 280 nm to detect the proteins migrating through the column. 
Proteins where eluted by outcompeting the proteins nickel affinity with free imidazole. The 
elution buffer had an imidazole concentration of 0.5 M and was raised in a gradient from 0% 
to 100%. The chromatogram displayed two peaks from the area where the elution buffer was 
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added (see Figure 13 to Figure 15). For C2 consisting of VH combined with LR and VL there 
were no clear peaks, the elution profile exhibited two shoulders that are barely distinct from 
the background absorbance (A280 ) caused by the increasing imidazole concentration. The first 
peak eluted when the gradient of elution buffer had reached ~40% (~200 mM imidazole) and 
the second peak eluted when the buffer over the column contained ~80% elution buffer 
(~400 mM imidazole). The fractions were separated on a polyacrylamide gel and it was 
concluded that the second peak corresponded to scFv with the correct size, see Figure 16. 
Since the flow-through still exhibited a band in the area corresponding to the size of scFv, the 
samples were loaded on the column a second time. After repeating the purification step, no 
scFvs were present in the elution fractions. The band in the flow through with a size similar to 
the scFvs is therefore probably not scFv, but rather the periplasmic chaperon FkpA. With a 
size of ~28 kDa, it is just a little smaller than the scFvs (~30 kDa). Since only one band was 
visible in the elution fractions (Figure 16), the samples were presumed to be pure. Therefore 
no further purification steps were done. The scFvs were dialysed against 50 mM Tris buffer 
and concentrated. 
 
Figure 13: IMAC of C1. Left: full chromatogram Right: zoomed elution peaks. The marked fractions, C10 and 
D11, correspond to peak 1 and 2 in the chromatogram, and are shown on gel in Figure 16. 
Blue graph: absorption at 280 nm. Red graph: absorption at 254 nm.  
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Figure 14: IMAC of C2 (left) and C3 (right), zoomed in on elution fractions. The marked fractions, C11 and D1 
for C2 and C8, D6 for C3, correspond to peak 1 and 2 in the chromatogram, and are shown on gel in Figure 16. 
Blue graph: absorption at 280 nm.  
 
Figure 15: IMAC of C4 zoomed in on the elution fractions. The marked fractions, C8 and D2 correspond to 
peak 1 and 2 in the chromatogram, and are shown on gel in Figure 16. Blue graph: absorption at 280 nm. 
 
 
Figure 16: IMAC fractions on polyacrylamide gels. It is difficult to see a band corresponding to C2 scFv, but 
there is a faint band presence seen by visual inspection. Collected fraction for peak number 1 and 2 are collected 
at highest absorbance (A280). The scFv are located in peak number 2, and are highlighted with a square in the 
figure.  
46 
4.2.4 Estimating the initial scFv constructs by ELISA 
MicroWell PolySorp solid plate (Sigma) wells were incubated with 100 µl NeuGc GM3 
ganglioside (10 µg/ml) in methanol (Prolabo), and allowed to evaporate overnight. Unspecific 
binding was blocked using 1x PBS containing 0.1% Tween 20 (Sigma) and 5% skimmed milk 
(AppliChem) (PBS-TM) and washed with 1x PBS with 0.1% Tween 20 (Sigma), between the 
different steps. After several trials of indirect ELISA with C1, C3 and C4, using a protein 
concentration range of 0.3 µg/ml – 15.6 µg/ml, no signal was seen (we thought at the time 
that the calculated concentration range was between 1 µg/ml – 5 µg/ml, see Section 3.4.2, 
page 27). We therefore started questioning the functionality of the scFv constructs. As 
discussed in Section 4.1.1, page 37, the His-tag was positioned N-terminally, placing it right 
next to the CDRs. The placement of the His-tag might have affected the scFvs activity. The 
following explanations for the failed experiments were considered and probed: 
1. Human mistakes made in the protocol. 
2. The NeuGc GM3 does not stick to the Polysorp surface of the wells and is washed away, 
leaving no ganglioside for scFv binding.  
3. The scFv concentrations used in the experiments were too low to give a readable signal.  
4. The secondary anti-His-tag antibody does not recognise the His-tag  
5. The scFv constructs do not bind to the NeuGc GM3 ganglioside. One reason might be that 
the His-tag disrupts antigen binding. 
1. Human mistakes are always a factor and can give variable results. Since the indirect ELISA 
was repeated at several occasions, all with a positive signal for the positive control and a 
negative signal for the negative control, this explanation was excluded. 
2. If the ganglioside does not bind to the plates, the blocking would make it difficult for other 
proteins to bind, as long as the proteins do not interact with the blocking agent itself. Since 
the negative control gave no signal, no cross reactivity between the scFvs and the blocking 
agent was observed. If the ganglioside does not bind to the plate, the positive control should 
not be able to bind either. A positive signal for mAb 14F7 at a concentration of 10 µg/ml was 
seen, confirming the presence of the ganglioside.  
3. A new indirect with a higher concentration range of 1 µ/ml – 100 µg/ml was conducted in a 
triplicate, but again no signal was observed. It is worth mentioning that the measured 
concentrations were initially overestimated by a factor of 3.2 (see explanation in Section 
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3.4.2, page 27). When adjusting the concentrations from the ELISA experiment, it was not 
1 µ/ml – 100 µg/ml, but 0.31 µ/ml – 31 µg/ml that were used. At the time it was assumed that 
the original concentrations were correct, and therefore this explanation was considered 
unlikely.  
4. Since the His-tag was placed at the N-terminus of the scFv constructs, it was possible that 
the His-tag was not accessible to the secondary antibody when the scFv was associated with 
the ganglioside. In order to investigate this explanation, a direct ELISAs was conducted with 
scFvs coated to the wells of the Nunc-Immuno 96 MicroWell MaxiSorp solid plates (Sigma), 
to confirm that the anti-His-tag antibody was capable of binding to the scFvs His-tag. The 
direct ELISA gave a concentration-dependent signal confirming the presence of the His-tag, 
and the functionality of the anti-His-tag antibody.  
5. Since the His-tag was localised close to, or within, the binding site, its presence might 
disturb NeuGc GM3 binding. In order to find out if the activity of the scFvs improves when 
the His-tag was removed, an alternative detection method for ELISA was required. Protein L, 
a protein with affinity for the variable light chain was suggested by Geir Åge Løset (Centre 
for Immune Regulation and Department of Biosciences, University of Oslo, Norway). A 
direct ELISA was performed where C1, C3 and C4 at a concentration of 15 µg/ml was 
detected with Protein L linked to horseradish peroxidase (HRP) (Protein L-HRP). A signal 
was observed for all three constructs, confirming that Protein L was able to bind to the scFv 
constructs. It was difficult to assess how the His-tag influenced the scFvs binding affinity. We 
therefore decided to remove the tag permanently from the vectors, and rather purify and detect 
the recombinant scFv constructs utilising Protein L. Of course, a way of detecting the 
His-tag’s influence would be to remove the His-tag using TEVp, and test the activity with 
Protein L-HRP in an indirect ELISA. But even after the removal of the His-tag, there would 
be two amino acids of the TEVp recognition site left, possibly disturbing NeuGc affinity. In 
order to test this, two different experiments were initiated in parallel: an activity test of C1 
with a TEVp-cleaved His-tag, and the cloning of His-tag free scFvs. An in-house-produced 
TEVp was used for cleaving off C1’s His-tag before an ELISA affinity test. Since the 
successful cleavage of the His-tag was difficult to determine, commercially available TEVp 
was ordered. No clear conclusion was reached as to the activity of the in-house-produced 
TEVp, and the ordered commercial TEVp did not arrive before the cloning and 
transformation of His-tag free scFvs were finished. Since Protein L gave the opportunity to 
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purify and detect scFvs without being dependent on a tag, we did not test His-tag scFvs when 
the commercial TEVp finally arrived. Instead we decided that future effort should be focussed 
on producing scFvs without a tag. 
There are several other possible reasons why the scFv constructs did not bind to NeuGc GM3. 
Maybe the Fv needs the stabilisation effect provided by the constant domains of the Fab for 
antigen binding. Another possibility is that the linker might restrict the scFvs, giving it the 
wrong conformation. One thing is certain: the scFv must have the correct 3D structure to be 
able to bind the ganglioside. Since it was possible to isolate three out of four scFvs from the 
periplasm, the isolated scFvs certainly form soluble proteins. 
4.3 Removing the His-tag 
To find out whether the His-tag influences the scFv activity, the His-tag and the TEVp-
recognition site were removed using oligonucleotide-directed mutagenesis. In the first attempt 
to remove the His-tag, the pFKPEN vectors containing the scFv’ His-tag constructs were 
digested with NcoI/NotI restriction enzymes and isolated using the QIAquick gel extraction 
kit (QIAGEN). The genes were amplified by PCR using a primer (Eurofins Genomics) that 
did not include the His-tag and TEVp recognition site. After isolating the PCR fragments, 
ligation and transformation, the negative control had 26 colonies, while the construct plates 
had around. Four colonies from each construct were sent to sequencing, none of the chosen 
colonies had the His-tag removed. In the second attempt the genes were amplified with PCR 
directly on the plasmid, using the same primers. The annealing temperature was raised from 
55 °C to 60 °C to avoid unspecific annealing, and as a control, every scFv gene was mixed 
separately with only forward or reverse primer and subjected to the same PCR conditions 
(Figure 17 shows the resulting PCR amplified DNA on a gel). The DNA concentrations from 
the isolated PCR fragments were low, therefore only 1000 ng DNA was used for re-digestion 
with NcoI/NotI restriction enzymes instead of the recommended 2000 ng. When digesting the 
original pFKPEN vector with NcoI/NotI restriction enzymes, CIP (NEB) was added to 
prevent vector re-ligation. After ligation and transformation into E. coli XL1-Blue cells, there 
were no colonies on the negative control, while the constructs had around 60 colonies. The 
sequencing confirmed complete removal of the His-tag sequence encoding portion and the 
TEVp recognition site, and preservation of the start codon and its relative position towards the 
lac promoter and Shine-Dalgarno sequence. The new constructs were denoted 14F7 scFv: 
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C1*, C2*, C3* and C4*. Table 2 gives general information about the different scFvs and a 
sketch of the new constructs are shown in Figure 18. 
Table 2: scFv protein information calculated based on the amino acid composition using 
ProtParam, ExPASy (Swiss Institute of Bioinformatics) (Artimo et al., 2012). 
 C1* C2* C3* C4* 
amino acids 255 255 255 255 
weight (kDa) 28.3 28.3 28.2 28.2 
pI 6.7 7.63 8.5 8.8 
ext. coefficient 
M
-1
 cm
-1
 
53080 54110 53080 54110 
absorption coefficient  1.88 1.90 1.88 1.92 
instability index 
(Below 40 indicate stable 
proteins) 
38.6 51.67 39.3 52.4 
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Figure 17: scFvs’ genes without a His-tag on a 1% agarose gel. The His-tag was removed during PCR by 
oligonucleotide-directed mutagenesis. The size of the new scFvs named C1*, C2*, C3* and C4* were reduced 
from 819 to 780 bp. In the wells with the reverse primer control (4, 7, 11 and 14) there are impurities. This might 
indicate that the reverse primer recognise a second site in the vector, or an impurity due to human mistakes. 
 
Figure 18: Overview. Removal of the His-tag from the scFv constructs. From the left: names and a block sketch 
of the scFvs with a His-tag. Mid-section: new names and a block sketch of the tag-free scFvs. To the right: a 
block sketch of the scFv domains connected by a linker. VH: variable heavy chain. VL: original 14F7 variable 
light chain. VL.A: alternative variable light chain. LC: elongated version of the linker obtained from our 
collaborators at CIM, Cuba. LR: linker obtained from Geir Åge at CIR, Rikshospital. The sketch-designed is 
inspired by Gunnarsen et al. (Gunnarsen et al., 2010).   
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4.4 scFv constructs without a His-tag 
4.4.1 Protein expression II 
During expression, the OD600 of the bacterial cultures was measured in a time-dependent 
fashion. An example of OD600 measurements during expression is provided in Table 3 
Bacterial culture samples were loaded on a polyacrylamide gel after normalising the amount 
according to the OD600 of the cultures by using the formula: OD
-1
 × 50 × nr of samples, and 
separated by SDS-PAGE, see Figure 19 and Figure 20. The factor 50 was chosen since 50 µl 
gave the best band-resolution for a bacterial culture with an OD of 1. The scFv size has been 
reduced from ~30 kDa to approximately 28 kDa when removing the His-tag. Since the 
chaperone FkpA has a very similar size to the scFvs (~28 kDa) a band was expected in all cell 
fractions. The chaperone is controlled by its native promoter and is supposed to be expressed 
continuously, and in a range of 20 to 30 times higher than the scFvs (Geir Åge Løset, G.R 
personal communication). A band at ~28 kDa was only seen in the medium of the overnight 
culture before removing the glucose (fraction 9 in Figure 19 and Figure 20) for C1*, C3* and 
C4*, and in the final fractions for both whole cells and medium for all four constructs 
(fraction 8 and 15 in Figure 19 and Figure 20). Since the band only occurs in overnight 
cultures it was probably the scFvs and not FkpA. The chaperone should have been expressed 
in high amounts throughout the cells’ growth cycle. If there had been more time, the question 
could have been answered using Western blotting. The scFvs can be detected with Protein L, 
followed by a re-blotting of the membrane to detect the FkpA utilising its FLAG-tag (see 
Figure 10 for a sketch of the FkpA chaperon). The result would make it clear which protein is 
present in which fractions. 
scFvs can be isolated from both cells and medium. Isolating protein from medium was time-
consuming as the medium had to be concentrated ten times to reduce the volume before 
affinity chromatography. Consequently, isolation from medium was only done for C4*, which 
had a much lower yield than to C1* and C3*. C2* was not optimised as sufficient material 
was available for the other scFvs. After expression, isolation, and purification, the average 
yield for the C1* scFv was ~5.5 mg per litre of E. coli culture, the C3 scFv had a yield of ~3.0 
mg, and the C4 scFv had a yield of ~0.1 mg per litre of E. coli culture. Compared to scFvs 
with a His-tag the yield was almost identical for C1* and C3*, both containing VL.A, but the 
yield was reduced significantly for C4*, with a decrease in the yield from 0.3 to 0.1 mg per 
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litre culture. A decrease could also be observed for C2*, the polyacrylamide gel had to be 
silver stained to be able to see a band, while a faint band could be observed for purified C2 
after IMAC with Coomassie staining The difference in expression, purification and activity is 
discussed further in Section 4.9, page 73. 
Table 3: An example of OD600 measurements taken during protein expression 
 C1*  C2* C3* C4* 
ON +glucose, 37 °C 1.3 1.6 1.6 1.5 
OD600 0.6 -0.8,+glucose, 37 °C 0.7 0.7 0.8 0.8 
t = 0 h, 30 °C 0.7 0.8 0.9 1.3 
t = 1 h, 30 °C 0.9 0.8 1.1 0.8 
t = 2 h, 30 °C 1.0 0.9 1.1 1.5 
t = 4 h, 30 °C 2.4 1.6 1.6 2.8 
ON 30 °C 4.5 3.3 3.4 5.1 
 
 
Figure 19: Expression test for C1* and C2*, the proteins are separated by SDS-PAGE. The whole cell fractions 
(C.) were normalised according to the OD. The medium was not normalised: 10 µl of medium (M) was loaded 
per sample for gel fractions 9 to 15. Samples were taken at different time points (t) during cell growth. A band 
corresponding to the size of scFv can be observed in gel fractions 8, 9 and 15 for C1* and in fraction 8 and 15 
for C2*. 
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Figure 20: Expression test for C3* and C4*, the proteins are separated by SDS-PAGE. The whole cell fractions 
(C.) were normalised according to the OD. The medium was not normalised: 10 µl of medium (M) was loaded 
per sample for fractions 9 to 15. Samples were taken at different time points (t) during cell growth. A band 
corresponding to the size of scFv can be observed in gel fractions 8, 9 and 15 for C3* and C4*. 
4.4.2 Purification 
Protein L affinity chromatography 
Protein L is a dimer with four binding sites for the variable light chain of antibodies. Protein L 
binds human κ-light chain 1, 3 and 4 as well as many murine κ-light chains (Kastern et al., 
1992, Graille et al., 2001). Both VL and VL.A are members of the murine κ subgroup, and 
should bind Protein L. Since the constructs were similar in size a separate column was used 
for each construct. This proved to be a good decision as the constructs containing the VL.A had 
a stretched-out elution profile (see Protein L elution fractions on gel in Figure 21 and 
Figure 22). This was probably due to the fact that Protein L has several binding sites for the 
variable light chain, generating avidity, making it difficult to elute the scFvs containing VL.A. 
In order to investigate if there were more available scFvs in the flow through, the flow 
through was added to the column a second time. Since there were almost no protein observed 
in the elution fractions it was concluded that one round over the column was sufficient.  
The elution pattern indicates a difference in Protein L and VL/VL.A binding, as scFvs with VL 
eluted quite quickly (see Figure 21 and Figure 22). When comparing the amino acid 
sequences of the two variable light chains with other light chains known to interact with 
Protein L, we found that VL was lacking two amino acids in the main Protein L binding 
region, while VL.A was lacking one amino acid (see Figure 23 for detailed information). This 
might be the reason why scFvs consisting of VL.A sticks to the column. The difference may 
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also be related to the amount of protein loaded onto the column. C1* and C3* consisting of 
the VL.M have a better expression pattern compared to C4* and C2*, which both contain the 
VL. The difference in affinity for Protein L might have implications for a potential quantitative 
comparison for scFvs affinity to the ganglioside in ELISA, since Protein L was used to detect 
binding.  
 
Figure 21: C1* (left) and C2* (right) isolated fractions by Protein L affinity chromatography column. C1*(to 
the left) is coloured Coomassie staining, C2* (to the right) is coloured by silver staining. 
 
Figure 22: C3* and C3* isolated fractions by Protein L affinity chromatography. C3*(to the left) and C4* (to 
the right) are both silver stained.  
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Figure 23: Alignment of amino acid sequence for VL.A and VL C1* and C3* consist of VL.A while C2 and C4 
consist of VL. Coloured in grey are amino acids with the correct R-group for Protein L interaction. Coloured in 
black are mismatch amino acids in positions that are important for Protein L interaction (Graille et al., 2001).  
Size-exclusion chromatography (SEC) 
When performing SPR with C1* and C4*, the resulting graph suggested a high degree of 
heterogeneity. To combat this, a second purification step was included in the purification 
protocol for the constructs without His-tag. The resulting chromatograms for the constructs 
showed two overlapping peaks (see Figure 24 and Figure 25). When analysing the fractions 
by SDS-PAGE, it was discovered that one of the peaks corresponded to a protein with a size 
of ~14 kDa (see Figure 26). The presence of this unknown band is discussed further in the 
next section. In order to separate the scFvs from the unknown protein, the proteins could be 
denatured by pre-incubating the sample with for example urea or guanidinium before SEC. 
Since the unknown protein elutes at approximately the same time as the scFv, it is assumed 
that it dimerise. By first denaturing the samples, the proteins will elute as monomers during 
SEC, separating the ~14 kDa from the ~28 kDa proteins. After SEC, the scFv must be 
refolded in vitro, but this might lead to a heterogenic sample, which is especially problematic 
for crystallisation. Also, by denaturing and refolding the scFvs, a portion of scFv will most 
likely be lost due to refolding problems, making this method sub-optimal for obtaining a high 
scFv concentration.  
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Figure 24: SEC chromatogram of C1* (left) and C2* (right). Marked fractions (J14, K3 for C1* and O3, O8 for 
C2) can be observed on gel in Figure 26. Blue-line: absorbance measured at 280 nm. Red-line: absorbance 
measured at 254 nm.  
 
Figure 25: SEC chromatogram of C3* (left) and C4* (right). Marked fractions can be observed on gel in 
Figure 26 Blue-line: absorbance measured at 280 nm. Red-line: absorbance measured at 254 nm. 
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Figure 26: SEC fractions from (from left) C1*, C2*, C3*, C4* separated on NuPAGE Bis-Tris 4-12% gel (Life 
technology) by SDS-PAGE. C1* is Coomassie stained, while C2*, C3* and C4* are silver stained. 
4.5 Additional band at ~14 kDa 
The unidentified protein with the approximate size of ~14kDa probably has the ability to 
dimerise non-covalently, forming a ~28kDa complex in solution. This would explain why it 
elutes during SEC in a peak overlapping with the scFvs. Since the unknown protein was co-
purified with scFv during Protein L chromatography it must have some degree of Protein L 
affinity. Two explanations for the origination of the protein were considered: 
1. The unknown protein is the scFv construct cleaved in two.  
2. The unknown protein might be lysozyme. 
1. The unidentified protein is approximately half the size of the scFv, making the suggestion 
that it is a cleaved version of the scFvs an attractive explanation. The most likely explanation 
would be that the scFvs are cleaved by a protease. If the cleaving is site specific, the 
recognition sequence is probably located in the consensus region flanking the linkers, since 
the cleaved scFvs consist of different linkers and variable light chains. When loading high 
concentrations of purified scFv on a NuPAGE Bis-Tris 4-12% gel (Life technology) several 
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bands between 10 and 28 kDa were observed, see Figure 27, possibly showing scFv split in 
several pieces by unspecific cleavage. Several proteases in E. coli cleave unspecifically by 
recognising exposed unstructured or hydrophobic regions. Perhaps the proteases degP or 
OmpT are responsible for the fragmented scFvs. DegP is the most likely candidate, located in 
the periplasm of E. coli, while OmpT is localised in the cytosol (Jones et al., 2002, Baneyx 
and Georgiou, 1990, White et al., 1995). An autolysis peptide sequence could also be 
responsible for the cleaving, or the fragmentation might occur due to a chemical added during 
protein isolation and purification. This is probably not the case, since the isolation and 
purification protocols are found in similar versions in several articles where single-chain 
proteins are produced (Schaefer and Plückthun, 2012, Gunnarsen et al., 2010, Kipriyanov et 
al., 1997). The bands for C1* highlighted in Figure 27, and the corresponding bands from 
C3* and C4* (not shown) were sent to mass spectrometry (MS) for identification. The protein 
was compared with the sequence of the four scFv constructs, the FkpA chaperone sequence 
and lysozyme. While waiting for the MS results, the second possibility that the unknown 
protein represents lysozyme was investigated further. 
2. Lysozyme is not known for interacting with Protein L, but since it was used in high 
concentrations (1 mg/ml) in the periplasmic expression protocol, it might be able to associate 
non-specifically with Protein L or the column material. Lysozyme also has the correct size, 
14 kDa, and has the ability to dimerise. Ion exchange chromatography (IEC) was considered 
as a method to separate the scFv with the unidentified protein based on its pI. However, since 
lysozyme (Sigma) has a pI of 9.3 and the C1*, C3*, C4* have a pI of 6.7, 8.5 and 8.8, 
respectively, the difference in pI is only large enough to perform IEC on C1*, but would not 
work for C3 and C4*. Since it was considered important to remove the unidentified proteins 
from all the samples, other separation techniques were conducted. To test if lysozyme binds 
Protein L at all, a concentrated lysozyme solution could have been added to the Protein L 
column, but this was not done since a method to separate the scFvs from the unidentified 
protein was still desired.  
To find out if the proteins elute at different pH, Protein L affinity chromatography was 
performed on C3* (with the protein composition seen in Figure 26), where the pH was 
lowered half a unit at the time. However, both proteins eluted at pH 3. 
C3* (with the protein composition seen in Figure 26) was mixed with an E. coli sample. Cell 
degradation was investigated after 1, 2, 4, 6 hours and compared with a negative control. If 
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the unknown protein was lysozyme, there should be an increase in cell death since lysozyme 
degrades bacterial cell walls. No increased degradation was observed. 
Since more protein was needed for further experiments, an alternative isolation without 
lysozyme was tested. The proteins were isolated by cracking the whole cells using a high 
pressure homogeniser (EmulsiFlex-C3, Avestin) (see the lab protocol in Section 3.2.2, 
page 2424). After Protein L affinity chromatography and SEC, followed by SDS-PAGE, the 
gel still showed the presence of the unidentified protein as shown in Figure 27. We could 
therefore conclude that the unidentified protein was not lysozyme. 
In the meantime, the MS results had arrived. By mapping the peptide sequence for the scFvs, 
it was revealed that the unidentified band at ~14 kDa consisted of scFv fragments (see Figure 
27 and Figure 28). It is clear that for the cleaved scFv, both the heavy and light chain are 
connected through Protein L affinity chromatography and SEC, as the MS results show 
peptide coverage from both variable chains. It is possible that the restriction sites 
HindIII/MluI are part of the recognition site for proteolytic cleavage, as they together with the 
flanks of the variable domains create a consensus sequence in all four scFvs. By replacing the 
restriction sites, the fractionation might be prevented, but the replacements must be 
considered thoroughly as most changes will affect the properties of the linker. One suggestion 
would be a linker constructed by Gunnarsen et al. where a leucine is mutated into a proline 
(L2P, linker numbering), destroying the HindIII recognition site in the gene sequence, and has 
a positive entropic effect on the linker’s flexibility (Geir Åge Løset, G.R personal 
communication) (Gunnarsen et al., 2010). But if the cleavage is performed by an unspecific 
protease such as degP, it might be necessary to transform the constructs into a degP-deficient 
E. coli strain. In order to find the best solution it would be beneficial to known why and where 
the scFvs are cut. One way of investigating where the scFvs are cleaved is by cleaving the 
scFvs with papain and send the fractions to MS. Papain cleaves C-terminally after Arg and 
Lys, all peptides formed by papain cleavage would therefore end on either Arg or Lys. If a 
peptide that does not end on Arg or Lys was detected, this would have to be cleaved by 
something else, and would indicate the cleavage site. 
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Figure 27: C1* SDS chromatograph and proteins isolated from cracked cells and separated by SDS-PAGE. 
Fraction at ~28, ~20, ~14 and ~10 kDa were sent to MS analysis. 
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Figure 28: MS results, peptide coverage, displayed in yellow are mapped using Scaffold 4 software (Proteomic 
Software Inc.).   
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4.6 Western blotting 
scFv run on a NuPAGE Bis-Tris 4-12% gel (Life technology) was stained by either 
Coomassie or silver staining. Coomassie staining makes it possible to estimate the quantity by 
comparing the stained scFv band with bands of protein with known concentrations, but it is 
not very sensitive. Silver staining is very sensitive, but does not say much about the amount of 
protein. Western blotting was used because it is both sensitive and quantitative, although the 
method usually needs some optimisation to get a good result.  
SEC fractions from C1*, C3* and C4* were subjected to SDS-PAGE. The fractions were 
blotted over to an Immobilon-P membrane. In the initiation trial the scFv were detected with 
Protein L-HRP using insoluble Tetramethylbenzidine (TMB), thereafter the insoluble TMB 
was exchanged for SuperSignal West Femto Chemiluminescent Substrate to detect scFvs 
(Thermo Scientific), the signal was visualised using Amersham Hyperfilm
™
 ECL in a dark 
room. When SuperSignal West Femto Chemiluminescent Substrate (Thermo Scientific) was 
used to detect scFv, a peculiar phenomenon occurred for C1* and C3* (see Figure 29 and 
Figure 30). Once the substrate was added, a clear yellow glow in full daylight was observed. 
The membranes were rushed into the darkroom for signal detection, but all the films showed 
halos around the areas that initially had projected such strong signal. Afterwards, the 
membranes of C1* and C3* were permanently stained in the areas where the halos were 
located, making re-blotting impossible (see permanently stained regions at the right hand side 
of Figure 30). The only normal Western blot was detected from C4* (see Figure 31). The halo 
phenomenon is probably due to too high protein concentrations. Possibly, the scFv 
concentration was so high that all the substrate was used up within the halo area, leaving no 
substrate left for Protein L-HRP. The outer part of the scFv band has a lower scFv 
concentration and can produce a continuous signal, creating the halo. Another explanation 
could be that the high scFv concentration packed the scFv so tightly that it was unavailable 
for Protein L-HRP binding. Consequently, Protein L-HRP would only be able to bind to the 
scFvs in the outline of the scFv band, where the protein concentration was lower, resulting in 
a signal distribution shaped like a halo. If there were more time, the western blot would have 
been repeated, this time with lower protein concentrations for constructs containing the VL.A 
(C1* and C3*) using the same detection system, and/or with a less sensitive detection system 
as for example SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific). Why 
the bands inside the halo were permanently stained is unclear. The permanent stains might be 
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a product of an unknown side reaction. Another possibility is that the substrate was cleaved so 
quickly that heat developed, permanently staining the membrane. 
Western blotting was also performed on an expression test, the same as discussed in Section 
4.4.1, and seen in Figure 19 and Figure 20. The expression test contained OD600 normalised 
whole cells, and medium detected at different times during the expression. The goal was to 
detect scFv, re-blot and detect the chaperone, by the FkpA’s anti-FLAG-tag. This would be 
very informative since C1*, C3*, C4* and the FkpA are of similar sizes, and the protein 
bands cannot be separated on a standard NuPAGE Bis-Tris 4-12% gel by SDS-PAGE. FkpA 
should have been expressed throughout the E. coli cell cycle, while the scFvs should have 
been expressed after glucose was removed. In the expression test, a band corresponding to 
scFv or FkpA was present in the whole cell fraction when glucose was removed, but not in the 
other whole cell fractions, indicating that FkpA is not expressed. In the initial Western 
blotting of the expression test, only C1* gave a readable signal. It was therefore decided to 
repeat the experiment, but load a larger number of whole cells on the polyacrylamide gel to 
increase the protein concentration. Regrettably there was not enough time left at this point to 
repeat the experiment. 
 
Figure 29: SEC chromatogram of C1* (left) and C4* (right) used for Western blotting. Emphasised fractions for 
C1* are separated on polyacrylamide gel in Figure 30, and separated in Figure 31 for C4*. Blue graph: 
absorption at 280 nm. Red graph: absorption at 250 nm. The absorbance is low because only a small volume of 
bacteria was produced 
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Figure 30: SEC fractions of C1* on Western blot. Membrane to the left: Signal developed from insoluble TMB. 
Membrane in the middle: Signal developed with SuperSignal West Femto Chemiluminescent (Thermo 
Scientific). Membrane to the right: Membrane after Chemiluminescent signal developing soaked in PBS for over 
one week. Concentrated C1*(conc. C1*) was obtained after Protein L affinity chromatography. The right picture 
is scaled to correspond to the molecular weight markers of the Western blot detected with insoluble TMB. 
 
Figure 31: SEC fraction of C4* on Western blot. The Standard originates from the original membrane and is 
proportionated using the permanently stained band from C3* originating from the same membrane as a guide. 
Concentrated C4* originates was obtained after Protein L affinity chromatography  
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4.7 scFv’s affinity for NeuGc GM3 
4.7.1 Testing the scFv-ganglioside affinity with ELISA 
Using indirect ELISA, ganglioside binding was tested using C1*, C3* and C4*. For signal-
detection Protein L-HRP was used. A signal was seen for the wells coated with NeuGc GM3, 
but not for the wells coated with the close relative NeuAc GM3, see Figure 32. This indicates 
that the removal of the His-tag solved the binding problems. When repeating the ELISAs a 
decrease in binding affinity was observed over time, first for C4* and then for C1*. Thus, a 
direct ELISA was performed, comparing the activity of an old and a new batch of C1* and 
C4* with the same concentration range. A weaker signal was perceived for the old batches 
compared to the new, demonstrating that the scFvs lose activity over time when stored at 
4 °C. An affinity test was performed to see if the scFv was stable after being frozen, and if 
glycerol should be added. The result showed that there was no loss in affinity after freezing 
at -80 °C, see Figure 33. The Figure also shows concentration-dependent binding for C1* 
towards the NeuGc GM3 ganglioside. The decrease in signal when 20% glycerol was added 
might be related to the viscosity of glycerol, making the sample concentration heterogenic. 
From that day all proteins were frozen at -80 °C in small aliquots and only fresh batches were 
used to ensure the highest degree of functionality for the scFvs.  
 
Figure 32: ELISA assay for plates coated with NeuGc GM3 or NeuAc GM3. Binding of the scFvs: C1* C3* and 
C4* in a concentration of 16 µg/ml are detected with Protein L-HRP in a double repeat. Since the ELISA assays 
were performed in a lab without ELISA reader, pictures were taken of the plates. The plate shows that the scFvs 
binds specifically to NeuGc GM3, and has no cross-reactivity towards NeuAc GM3. C3* only displays a weak 
signal in the upper repetition due to human errors. 
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Figure 33: Three aliquots of C1* with at three different concentrations were used to see if the protein was 
harmed by being frozen at -80 °C with and without 20% glycerol. The aliquots were fresh and stored for 24 
hours in either fridge or freezer before being used in the ELISA assay. The affinity is measured at three different 
concentrations, each consisting of three aliquots, displaying concentration-dependent binding to NeuGc GM3. 
Since the ELISA assays were performed in a lab without ELISA reader, pictures were taken of the plates. The 
positive and negative controls are outside the scope of this picture but reported a positive and negative signal, 
respectively. The result was a concentration-dependent signal, and showed that C1*could be frozen at -80 °C 
without the addition of glycerol. 
4.7.2 Surface plasmon resonance (SPR) 
SPR was performed for C1* and C4* in a single-cycle experiment, on a CM5 chip (GE 
Healthcare) coated with the NeuGc GM3 ganglioside. When ganglioside was immobilised on 
the CM5 chip, the reference value was 75, if the value had been below 50 the chip would have 
had to be recoated. The 14F7 mAb was used as a control and displayed the same signal before 
and after the experiment, verifying that no measurable amount of ganglioside was lost during 
the experiment. The signal was interpreted by Rune Johansen Forstrøm (Engineer at Oslo 
University Hospital, Oslo). SPR was only performed for C1* and C4*, as these were the two 
constructs with the highest diversity in amino acid sequence and available in appropriate 
concentrations. For C4*, the graph was judged invalid, probably due to protein aggregation. It 
was possible to obtain a binding constant for C1*, but it required extensive, optimistic fitting. 
C1* (Figure 34) display heterogeneity and artefacts, it was possible to obtain a binding 
constant for C1* (~28 µM), but it does not properly fit the data, and is not trustworthy. But, 
the graph does display binding towards the NeuGc GM3 ganglioside, confirming the ELISA 
results. The samples used in SPR had been stored at 4 °C for several weeks. Thus, the low 
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quality data might originate from bad samples (see Section 4.7.1, page 65). To obtain more 
reliable data, the SPR experiment should be repeated with fresh samples. 
 
Figure 34: SPR result for C1* binding to NeuGc GM3 in a single-cycle experiment. 
4.7.3 ThermoFluor 
Since binding of a ligand often stabilises protein structure, we wanted to use ThermoFluor to 
see if we could detect a shift in the melting temperature when the antigen was added to the 
scFvs. C1*, C3* and C4* were used at a concentration of 30 µg/ml (believed at the time to be 
0.1 mg/ml, see explanation in Section 3.4.2, page 27). The proteins were mixed with 
increasing concentrations of the soluble NeuGc GM3 derivative called Tricer, or the NeuGc 
GM3 ganglioside.  
In Figure 35, the three scFvs with and without Tricer are plotted in a normalised graph. C1* 
and C4* are the two scFvs with the highest diversity in the amino acid sequence. C1* consists 
of LR and VL.A, while C4* consists of LC combined with VL. C1* was significantly more 
stable than C4 *, with a difference in melting temperature of around 20 °C. We could not 
observe any differences in the C1* and C4* graphs after adding Tricer. It is important to 
remember that it was no guarantee that Tricer would bind to 14F7 at all, since the 
consequences of removing a most of the ceramide moiety have never been assessed, due to 
low available amounts of Tricer. The fact that there were no shifts in the melting curves might 
indicate that Tricer did not bind to the scFvs, or that binding did not lead to increased 
stability. 
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For C3*, consisting of LC combined with VL.A, we saw a small shift in the curve when Tricer 
was present, indicating higher stability, but the overall melting temperature stayed the same. 
The cleaved scFv fragments, with an approximate size of 14 kDa, probably dissociate when 
the temperature is increased. This will make them denature faster, giving them a different 
melting curve with a lower average melting temperature compared to a sample consisting of 
pure full-size scFv. A heterogeneous sample used for ThermoFluor, consisting of both 
cleaved and full-size scFv, will display a melting curve that is in reality an average of the two 
melting curves. The consequence is that the percentage of fragmented scFv in a sample will 
affect the resulting melting curve, and the calculated melting temperature. Especially C3* had 
a high percentage of fragmented scFv, as seen in Figure 26, and the calculated melting 
temperature can therefore not be trusted. The heterogeneity in the sample might also explain 
the shoulder present in the C3* curve without Tricer, in Figure 35. Perhaps it is in the 
shoulder area that the cleaved scFvs are completely denatured, resulting in a short levelling 
period before the curve continues to rise, due to denatured full-size scFv. In order to obtain 
trustworthy ThermoFluor data the fragmented scFv has to be removed. 
When the scFvs were mixed with the NeuGc GM3 ganglioside, methanol was added to make 
the ganglioside soluble. The hydrophobic environment decreased the overall melting 
temperatures for all scFvs. There is a visible difference between the C3* curves with and 
without NeuGc GM3 in Figure 36. The shoulder shown in Figure 36 for C3* levels out in the 
presence of NeuGc GM3, resulting in a plateau, before the curve continues to rise. If the 
perceived shoulder is due to cleaved scFvs, NeuGc GM3 binding has a positive effect on the 
stability of the cleaved scFvs. Both curves overlap in the main peak, indicating that NeuGc 
GM3 does not influence full-size scFv in the same manner. If the shoulder originates from the 
cleaved scFv, the correct melting temperature would be higher. An expected melting curve is 
modelled into Figure 36 marked by a blue dotted line. In order to obtain valid scFv melting 
curves, ThermoFluor has to be repeated with samples containing only full-size scFvs. C4* 
had a small shift in the curve when the ganglioside was present (data not shown) while the 
curve for C1* together with ganglioside had an invalid fit, probably due to the methanol 
concentration.  
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Figure 35: ThermoFluor. C1*, C3*,and C4* have melting temperatures of 71.5 °C, 63.7 °C and 51 °C, 
respectively. 
 
Figure 36: ThermoFluor result of C3* with and without the NeuGc GM3 ganglioside. The shoulder seen at 
approximately 53 °C levels out in the presence of ganglioside and the melting temperature shifts from 50 °C to 
51 °C. The shoulder might originate from cleaved scFv, while the main peak might correspond to full-size scFv. 
A blue dotted curve is modelled into the graph representing the expected melting curve for purified full-size C3* 
scFv with a melting temperature of approximately 54 °C. 
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4.8 Protein Crystallisation 
The two most common techniques for determining protein structure are nuclear magnetic 
resonance (NMR) spectroscopy and X-ray crystallography. The methods can be used to find 
the structure of a free protein or for a protein associated with a binding partner (Blow, 2002). 
For a protein binding a small ligand, X-ray crystallography might have an advantage 
compared to NMR for low-affinity binding. Since NMR obtains the structure from proteins in 
solution, the proteins can move around freely, making it difficult to detect the small ligand’s 
precise binding conformation. In X-ray crystallography it is possible to obtain a higher 
precision, as the structure is detected from a crystal where the proteins are arranged in a rigid 
lattice structure. 
To obtain a 3D model of a protein using X-ray crystallography it is not enough to just expose 
it to X-rays, the scattering effect for a single molecule is too weak. A crystal is necessary, 
because the lattice structure amplifies the scattering signal resulting in a molecule-dependent 
scattering pattern known as the diffraction pattern (Sheehan, 2009, Blow, 2002). The rate-
limiting step in X-ray crystallography is very often protein crystallisation. In order to obtain a 
crystal, proteins are mixed with different additives and salt concentrations under a variety of 
pH ranges and temperatures. It is especially challenging to crystallise a full-size antibody, as 
it is a highly complex and flexible molecule. By using scFv the complexity is reduced 
increasing the chance for crystal formation. 
Purified C1* at a concentration of 3.2 mg/ml in 50 mM Tris-HCl (Chalbiocem) buffer was 
mixed with the soluble derivative of the NeuGc GM3 ganglioside named Tricer and incubated 
for 1 hour, see Figure 7 for Tricer’s molecular composition. The optimal molar antigen 
concentration should be 10 to 50 times higher compared to the molar concentration of scFv. 
Since Tricer was only available in very small amounts, we used approximately 10 times more 
Tricer compared to scFv before setting up the crystallisation screens. 
The crystal screening was a continuing process throughout the master thesis. For initial 
screening the Oryx4 (Douglas Instruments) was used. One drop had a volume of 0.4 µl, 
containing 50% reservoir solution and 50% protein. Several commercial kits were used for 
screening as indicated in the Appendix, Table S7. 
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After trying out several screening conditions, two hits were detected in the Morpheus screen, 
C8 and G8 (Molecular dimensions). The conditions are listed in the Appendix Section G: 
Crystallisation screens, page S31. The compositions of Morpheus screen buffers C8 and G8 
were used for setting up an optimisation screen containing several large drops with slight 
deviations from the original conditions and with differences in protein, screening buffer 
composition. See the Appendix, Section G: Crystallisation screens Optimisation, 
crystallisation hits Table S29 and Table S30, page S33 for an example. From the optimised 
screen, crystals formed readily when the pH was varied between 7 and 8. Two promising 
crystals also formed in the well for G8, where the only additive was 0.5 M sodium oxamate. 
The larger of the two crystals was sent to the European Synchrotron and Radiation Facility 
(ESRF), Grenoble, France, for diffraction experiments, but the crystal did not diffract. 
In several wells in the optimisation screen many small crystals formed (see Figure 37 and 
Figure 38 and the Appendix Section G: Crystallisation screens, Optimisation, crystallisation 
hits, page S33 ). A large crystal was desired, as it has better probability to diffract. A more 
extensive lattice might result in diffraction data with higher intensity spots, giving better 
resolution. To achieve this, new optimisation screens were prepared using 75% buffer and 
25% protein. As in the initial optimisation screen several small crystals formed, but this time 
some larger crystals were observed. These were sent to the ESRF, Grenoble, France, for 
diffraction experiments, without success. The crystals did either not diffract, or displayed 
large spots, indicating salt crystals. An example is seen in Figure 39. 
If there were more time available, seeding would be a method that might help form larger 
scFv-Tricer crystals. The small crystals can act as seeds for further crystal growth, resulting in 
larger crystals. If more time and protein were accessible, the scFvs should be crystallised 
alone, without the addition of Tricer, since the antigen is available only in small amounts. If 
diffracting crystals are obtained, crystals formed under the same or similar conditions could 
be soaked with Tricer. If successful, this procedure would make it possible to obtain the 
structure of scFv with and without Tricer, giving the ability to investigate potential 
conformation differences between the crystals, and minimising the use of Tricer.  
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Figure 37: Crystals formed in C8 Morpheus screen. Left: Crystals formed during initial screening conditions, 
Right: Crystal produced during optimised screening conditions. The size proportions for the two pictures are not 
correlated. 
 
Figure 38: Crystals formed in G8 Morpheus screen. Left: Crystals formed during initial screening conditions, 
Right: Crystal produced during optimised screening conditions. The size proportions for the two pictures are not 
correlated.  
 
Figure 39: Left: A crystal in a crystal loop. Right: Diffraction of the crystal, the well-separated, large spots 
indicates salt crystals.  
73 
 
4.9 Comparison of the scFv constructs 
The stability index seen in Table 4 indicates that the presence of a hydrophilic His-tag helped 
to solubilise the scFvs, making them more stable. The pI is in a range between 6.7 for C1* 
and 8.8 for C4* (see Table 4). The linker is mainly responsible for the difference in pI, since 
LR has a total charge of minus one, while LC has a total charge of plus two (see aligned linker 
sequence in Figure 40). When removing the His-tag from the scFvs a decrease in the yield 
was perceived for C4*, consisting of the original 14F7’s VL. The yield decreased from 0.3 mg 
to 0.1 mg per litre bacterial culture, when compared to C4 with C4*, respectively (C4 has a 
His-tag and was purified using IMAC) while C2* was not obtainable in sufficient amounts for 
effective isolation. The yield for C1* and C3*, both consisting of VL.A, stayed approximately 
at the same level, with a yield of 5 and 3 mg per litre bacterial culture, respectively. It can 
therefore be concluded that that the scFvs containing VL.A (C1*/C3*) compared to scFvs 
containing VL (C2*/C4*), express better in a prokaryotic system. The decrease in yield for 
scFvs containing the VL might have originated in reduced solubility when the His-tag was 
removed, or because the VL has low affinity to Protein L and was therefore not efficiently 
purified. Since no scFv was detected the second time over the Protein L column a possibility 
would be that Protein L only associated with C2* and C4*, explaining the decrease in yield. 
All ELISA experiments were detected by visual inspection, since no ELISA reader was 
available at the laboratory and the plates could not be frozen. Therefore, the difference in 
affinity towards the NeuGc GM3 ganglioside was not estimated quantitatively, but binding 
was detected for all four scFvs confirming conserved affinity towards the NeuGc GM3 
ganglioside. In ThermoFluor, C1* containing VL.A had ~20 °C higher melting temperature 
compared to C4* containing VL. It can therefore be concluded that scFvs containing VL.A are 
more stable.  
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Table 4: The scFv constructs with and without His-tag. The information was obtained using 
ProtParam, ExPASy (Swiss Institute of Bioinformatics) (Artimo et al., 2012). 
 C1 C1* C2 C2* C3 C3* C4 C4* 
amino acids 268 255 268 255 268 255 268 255 
weight (kDa) 30.0 28.3 30.0 28.3 29.9 28.2 29.96 28.2 
pI 6.7 6.7 7.1 7.63 8.2 8.5 8.6 8.8 
ext. coefficient 54570 53080 55600 54110 54570 53080 55600 54110 
absorption 
coefficient  
1.82 1.88 1.86 1.90 1.83 1.88 1.85 1.92 
instability index 
(Below 40 
indicate stable 
proteins) 
36.9 38.6 49.3 51.67 37.5 39.3 50.0 52.4 
 
 
Figure 40: ClustalW2, EMBL-EBI alignment of the amino acid sequence of C1* and C4*. The CDRs and the 
linkers are marked with a black line above the amino acid sequence, the CDRs are localised using IMGT/V-
QUEST. The original linker from Cuba (LC.O) is highlighted in light grey (Larkin et al., 2007, Brochet et al., 
2008, Giudicelli et al., 2011).  
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5 Methodological considerations and 
  future perspectives 
5.1 Optimising the scFv constructs 
In the beginning, it was not known if it was possible to produce one, several, or all the scFv 
constructs. When three out of four constructs were expressed in sufficient amounts to 
continue with further experiments, no additional effort was made to optimise the C2/C2* 
expression. The sequence analysis shows that the C2/C2* constructs are correct, but it might 
be advisable to subclone the construct once more in case there is something wrong within the 
vector. 
To prevent scFv cleavage the cause should be found. If it was cleaved by an unspecific 
protease, it might be possible to prevent the cleaving by isolating the scFvs earlier without 
incubating the cells overnight. To investigate this, scFvs can be isolated from the cells at 
different time points and, and after normalising the samples and SDS-PAGE the ratio of full-
size scFvs vs cleaved scFvs can be compared with Western blotting. Also, by looking at the 
expression tests (see Figure 19 and Figure 20) it is unclear if the periplasmic chaperone FkpA 
is expressed at all since it is not visible on the polyacrylamide gel. If this is the case, the 
introduction of FkpA in E. coli might help solubilising the scFv, increasing the yield and 
minimising scFv cleavage. One method would be to subclone the construct once more into 
pFKPEN, or to change to the pFKPEI vector, where the FkpA chaperone is transcribed as the 
second open reading frame in a discistronic constellation with the scFv, where both are 
controlled by the lacPO (Gunnarsen et al., 2010).  
In the addition to FkpA expression, the yield might be increased by reintroducing a, both in 
respect to solubility, purification and to be able to detect the binding affinity quantitatively. 
Since an N-terminus tag probably disrupt antigen binding the tag should preferably be placed 
at the scFvs C-terminus. A C-terminal tag cannot be removed by TEVp without leaving a 
flexible peptide tail at the C-terminus, possibly disturbing crystal formation. If possible, an 
alternative would be to introduce a recognition site for a different protease, which cleaves 
such that a minimum of amino acids are left at the C-terminus. Tagged proteins can still 
crystallise, although flexible elements are generally not beneficial for crystal formation. 
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Therefore, the choice of solution depends on the ultimate target: to characterise the different 
scFvs or to optimise the scFvs for crystallisation studies. 
5.2 How the presence of Tricer effects the experiments 
When ThermoFluor and crystallisation screening was executed, Tricer was used as a 
replacement for the NeuGc GM3 ganglioside. Tricer contains part of the ceramide moiety and 
was made soluble by the addition of an acetamide group. It is not known how the partial 
removal of the ceramide portion affects antigen binding. The binding affinity could be 
assessed using ELISA or SPR, but since only small amounts of Tricer were available, it was 
not possible to conduct any quantitative experiments. Since we do not know if Tricer is a 
worthy replacement of the NeuGc GM3 ganglioside, ThermoFluor cannot be used as a 
method to assess if the NeuGc GM3 ganglioside stabilise the scFvs. It would also be 
beneficial to produce scFv crystals without the addition of Tricer, and rather soak in Tricer 
afterwards, when diffracting crystals are obtained.  
5.3 Ganglioside affinity estimated by ELISA 
Since there was no ELISA reader available at the laboratory, and the plates could not be read 
after having been frozen, all-important ELISAs should have been repeated in a laboratory 
containing an ELISA reader giving quantitative data. But since there is a probability that 
Protein L has a higher affinity towards scFvs containing VL.A (C1*/C3*), compared to scFvs 
consisting of VL (C2*/C4*), another detection method would be advisable so that a more 
trustworthy quantitative comparison of the scFvs affinity towards the NeuGc GM3 
ganglioside could be executed. In order to detect the scFvs a tag would be beneficial. Since 
the original N-terminally His-tag probably disturbed antigen binding, an alternative would be 
to place the His-tag at the C-terminus. This would create the opportunity to purify the scFvs 
using IMAC and to detect the NeuGc GM3 affinity with an anti-His-tag antibody.  
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5.4 General thoughts for future experimental procedures 
Several of the experiments should be repeated to give more weight to the results, and to rule 
out uncertainties: ThermoFluor and SPR should both be repeated with fresh, homogenous 
samples, as heterogeneity can affect the results. SPR should preferable be repeated in a 
multiple-cycle mode instead of single-cycle mode. In the single-cycle mode, all protein 
samples were injected continuously, giving possible overlap, while in a multiple-cycle mode 
the channels would be cleaned with NaOH between sample injections. An experiment that 
might be recommended for further stability characterisation is circular dichroism (CD). CD 
gives information about the secondary structure. By comparing the CD spectra from the scFvs 
with known scFv spectra of clean scFv samples, it is possible to detect if there is a higher or 
lower degree of unstructured elements presence. In order to get a reliable result, the sample 
must consist of only full-size scFv, without any cleaved fragments, since the cleaved 
fragments are probably less structured. 
To increase the chance to obtain a diffracting crystal, it would be beneficial to undertake 
crystallisation with scFv variants containing different variable light chains. Future work could 
be narrowed down to C1 or C3 combined with C4, all with a C-terminal tag. C1 containing LR 
and VL.A give the best yield, and has the highest amino acid diversity compared to C4 with LC 
and VL. But C3 with LC and VL.A has the same linker as C4, making it easier to verify the 
effect of the light chain, without the presence of a second parameter, the linker. If the 
expression problem with C2 was solved, and the scFv gave the same or a better yield 
compared to C4, then C1 and C2 would be the optimal constructs to use for further 
experiments because of C1’s high expression yield. 
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6 Summary and conclusion 
Cancer is a disease that is treated by a range of different methods, where the most common 
ones also weaken the healthy cells within the body. This makes cancer medicine a research 
field with a high potential for improvement. 14F7 mAb has the nickname The Assassin, 
because it specifically kills tumours without harming healthy human cells. In order to fully 
exploit the favourable qualities of 14F7, it is important to understand how it binds to its 
antigen, the tumour specific NeuGc GM3 ganglioside. This knowledge can be used to 
generate the next generation of ganglioside-specific antibodies and provide general insight 
into how antibodies interact with gangliosides. Different methods have been tested to 
understand the interaction between the antibody and its antigen (Abshiru, 2010, Rojas et al., 
2012, Krengel et al., 2004). In 2004, the structure of Fab was solved by X-ray 
crystallography, but the crystals are difficult to reproduce (Krengel et al., 2004). To obtain an 
experimentally valid model of the complex, the first step would be to reproduce crystals, then 
soak in NeuGc GM3 or co-crystallise the complex. We decided to initiate an alternative 
strategy by producing 14F7 scFvs. 
In this thesis, we designed four scFv versions of 14F7, which were expressed and isolated 
from the periplasm of E. coli. Since scFvs are less complex than Fabs, we hoped that we 
would improve the chances of obtaining crystals. We managed to grow crystals, but since 
they did not diffract, further optimisation is needed. scFv consists of a variable heavy chain, 
and a variable light chain, connected with a linker. In order to improve the chances of 
producing functional scFvs, the variable heavy chain of 14F7was combined with one of two 
different linkers, and either the original or an alternative variable light chain. All constructs 
proved to bind to the NeuGc GM3 ganglioside, as shown by SPR and ELISA. The scFvs 
consisting of the alternative variable light chain had a significant higher yield compared to the 
scFvs with the original 14F7 variable light chain. The scFvs with the alternative light chain 
also had an increased stability as shown with ThermoFluor. 
This thesis sets the foundation for further scFv characterisation, and provides the tools to 
produce 14F7 scFv crystals. We believe, and hope, that diffracting crystals are now within 
reach, and that this thesis will contribute to solve the mystery of how 14F7 binds and interacts 
with its tumour-specific antigen. 
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7 Appendix 
Section A: Materials 
Table S1: Reagents 
 
Chemicals 
 
Vendor 
-mercaptoethanol Sigma 
λHindIII, molecular weight marker Fermentas 
ΦX174, molecular weight marker New England Biolabs 
1 kbp DNA ladder New England Biolabs 
100 bp DNA ladder New England Biolabs 
14F7 mAb form collaboration partners CIM 
3’,5,5’-tetramethylbenzidine (TMB), insoluble Chalbiocem 
3’,5,5’- tetramethylbenzidine (TMB), soluble Chalbiocem 
agarose Lonza 
Acetic Acid Merck 
Alkaline Phosphatase, Calf Intestinal, (CIP)  New England Biolabs 
Anti-poly Histidine-Alkaline phosphatase antibody Sigma 
Ampicillin AppliChem 
Bio-Rad Protein Assay Bio-Rad Laboratories 
Bovine serum albumin (BSA, 100x) New England Biolabs 
Buffer #3, 10x New England Biolabs 
Buffer #3.1, 10x New England Biolabs 
cOmplete inhibitor Roche 
Coomassie Brilliant Blue G250 Amersham Biosciences 
Dibasic sodium phosphate (Na2HPO4) G-Biosciences 
Dithiothreitol (DTT) Bio-Rad Laboratories 
S2 
DNA constructs Invitrogen 
DNA Loading Dye Solution (6x) Lonza 
DNase  AppliChem 
dNTP mix Invitrogen 
E. coli XL1-Blue Stratagene 
Ethanol (Absolut Prima) Arcus 
Ethylenediaminetetraacetic acid (EDTA) Fluka 
Formaldehyde (CH2O) Prolabo 
D-(+)-Glucose Sigma 
Glycerol Prolabo 
Glycine Sigma 
HBS-EP buffer GE Healthcare 
HBS-N buffer GE Healthcare 
HindIII restriction enzyme New England Biolabs 
Hydrogen-Chloride (HCl) Merck 
Imidazole Sigma 
Isopropyl--D-Thiogalactopyranoside (IPTG) Sigma 
Ligase buffer, 10x New England Biolabs 
Lysozyme Sigma 
Methanol Prolabo 
MES SDS Running buffer, 20x Invitrogen 
Milli-Q H2O (MQ- H2O) Millipore 
MluI restriction enzyme New England Biolabs 
Mono Sodium phosphate (NaH2PO4) Fluka 
NeuGc GM3, from collaboration partners CIM 
NcoI restriction enzyme New England Biolabs 
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NuPAGE loading buffer (4x) Invitrogen 
Nickel(II) sulphate (NiSO4) Sigma 
NotI restriction enzyme New England Biolabs 
NuPAGE LDS Sample buffer  Invitrogen 
NuPAGE® LDS Sample Buffer (4X) Invitrogen 
P20 detergent GE Healthcare 
PEG solutions Fluka 
Peptone from casein Merck 
Phosphate buffered saline (PBS) Life technology 
Phusion DNA polymerase, 2U/µl Thermo Scientific 
Phusion reaction buffer, 5x Thermo Scientific 
Potassium Ferricyanide (K3Fe(CN)6) Sigma 
Potassiumphosphate, mono (KH4PO4) Fluka 
Primers, PCR Eurofins Genomics 
Primers, Sequencing Metabion 
p-nitrophenylphosphate substrate (pNPP) Sigma 
2-Propanol Sigma 
Protein L-HRP Genscript 
RNase A Sigma 
SeeBlue
®
 Plus2 standard, molecular weight marker Invitrogen 
Silver nitrate (AgNO3) Merck 
Skimmed milk (dried) AppliChem 
Sodium carbonate (Na2CO3) Sigma 
Sodium chloride (NaCl)  Prolabo 
Sodium citrate (Na3C6H5O7) Sigma 
Sodium hydroxide (NaOH) Kebo Lab 
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Sodium thiosulfate (Na2S2O3) Sigma 
D-(+)-Sucrose Fluka 
SYBR Safe DNA gel stain (100x) Invitrogen 
SYPRO Orange Sigma 
Synthesised 14F7 scFv genes  Life technology 
T4 DNA ligase  New England Biolabs 
T4 DNA ligase buffer (10x) New England Biolabs 
Tris Base Chalbiocem 
Tris-hydrogencloride (Tris-HCl) Chalbiocem 
Tween 20 Sigma 
Urea Merck 
Yeast Extract, granulated Merck 
 
Table S2: Chromatographic Column Materials 
Materials Manufacturer 
Chelating Sepharose  GE healthcare 
Protein L capto resin GE Healthcare, 
Superdex 200 R10/300 Column GE Healthcare 
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Table S3: Equipment 
Equipment Manufacturer 
Amersham Hyperfilm ECL GE healthcare 
Amicon Ultra free tubes Millipore 
Amicon ultra filter, Ultracell-10 K, 2 ml Millipore 
Amicon ultra filter, Ultracell-10 K, 15 ml Millipore 
CM5 chip GE Healthcare 
Crystal Clear Sealing Tape Hampton 
Cuvettes Sarstedt 
Crystallisation Plate, 96 MRC SWISSCI 
Eppendorf tubes, 1.5 ml and 2 ml Eppendorf 
Extra thick paper blot paper Bio-Rad Laboratories 
Immobilon-P membrane Millipore 
LightCycle, 480 Sealing foil Roche 
LightCycle, 480 Plate 384 Roche 
NuPAGE Bis-Tris 4-12% gel  Life technology 
Nunc-Immuno 96 MicroWell MaxiSorp and 
PolySorb solid plates 
Sigma 
Optifit Refill Tips Sartorius 
PCR Cuvette Eppendorf 
Petman pipettes Gilson 
Rapid Flow, 20 µm, 150 ml, filter Nalgene 
Siliconized cover slides Hampton Research 
SuperSignal West Femto Chemiluminescent 
Substrate 
Thermo Scientific 
TPP
®
 tissue culture plates, 24 well Sigma 
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Table S4: Software 
Software Vendor 
Ape By Wayne Davis 
Clustal2W EMBL-EBI 
GraphPad Prism v5 GraphPad software Ink 
LightCycle software Roche 
Paint Microsoft 
ProtParam, ExPASy  Swiss Institute of Bioinformatics 
PyMOL Schrödinger 
Scaffold 4 Proteomic Software Inc. 
Unicorn 5.11 GE Healthcare 
V-QUEST IMGT 
Wasp Run  Douglas Instruments 
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Table S5: Equipment 
Machines Vendor 
ÄKTApurifier-900 GE Healthcare 
Avanti Centrifuge J-26 XP Beckman Coulter 
Biofuge Fresco, Heraeus Thermo Scientific 
Capsulefuge, TOMY PMC-060  Tomyteck 
Centrifuge 5810 R Eppendorf 
Electrophoresis power supply-EPS 601 GE healthcare 
EmulsiFlex-C3 Avestin 
Eppendorf Thermomixer comfort Eppendorf 
Gel logic 200 image system Kodak 
LightCycle 480 Roche 
Mini Horizontal Submarine Unit GE Healthcare 
Miniorbital shaker Stuart 
Multitron II Infors 
MQ-H2O, Direct Q Millipore 
Nanodrop 2000c Thermo Scientific 
NanoPhotometer  IMPLEN 
Novex Mini-Cell Invitrogen 
Orbitrap-XL  Thermo Fisher 
Oryx4 robot  Douglas Instruments 
Peltier Thermal Cycler (PTC) -200 MJ Research 
PowerPack HC power supply Bio-Rad Laboratories 
Trans-Blot SD Semi-Dry Transfer Cell Bio-Rad Laboratories 
Tuttnauer 3870-ML, autoclave Tuttnauer 
Ultraspec III KKB Pharmacia 
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Table S6: Kits 
Kit Vendor 
Nucleo Spin Plasmid kit  Macherey-Nagel GmbH & Co. KG 
PCR Purification Kit (250)  QIAGEN 
QIAprep Spin Miniprep Kit QIAGEN 
QIAquick gel extraction kit QIAGEN 
 
Table S7: Crystallisation Kits 
Crystallisation kit Vendor 
JCSG Molecular Dimensions 
JCSG++ Molecular Dimensions 
Morpheus Molecular Dimensions 
Morpheus (added Ca
2+
) Molecular Dimensions 
Morpheus MDI-46 Molecular Dimensions 
PGA Molecular Dimensions 
PACT Molecular Dimensions 
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Section B: Solutions, buffers and gels  
All reagents are listed in Table S1: Reagents 
Media 
 
Protein extraction 
 
  
LB medium 2x YT 
10 g Peptone 16 g Peptone 
5 g Yeast extract 10 g Yeast extract 
10 g HCl 5 g NaCl 
pH 7.1 pH 7.8 
MQ-H2O to final volume of 1 L MQ-H2O to final volume of 1 L 
Autoclaved, and stored at 4 °C Autoclaved, and stored at 4 °C 
Periplasmic extraction solution Cell cracking buffer 
20% Sucrose 50 mM Tris-HCl 
50 mM  Tris-HCl 150 mM NaCl 
1 mM EDTA 1 mM EDTA 
pH 7.8 2 µg/ml DNase 
   1 tab Per 100 ml  
cOmplete inhibitor 
 pH 7.8 
Cell cracking wash buffer Protein storage buffer 
50 mM Tris-HCl 50 mM Tris-HCl 
150  mM NaCl    
pH 7.8    
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Purification buffers 
 
 
 
Pre-purification protein adjustment-IMAC  
80 ml Soluble periplasm    
4  ml 1 M Tric-HCl    
1.8 ml 1 M Imidazole    
24 ml IMAC binding buffer    
pH 7.8  
IMAC binding buffer IMAC elution buffer 
20 mM Imidazole 0.5 M Imidazole 
50 mM Tris-HCl 50 mM Tris-HCl 
0.5 M NaCl 0.5 M NaCl 
pH 7.8  pH 7.8 
The buffer is filtered and degassed before use The buffer is filtered and degassed 
before use 
Pre-purification protein adjustment 
-Protein L, C1 and C3 
Protein L binding buffer 
80 ml Soluble periplasm 20 mM Sodium phosphate 
14 ml 1 M Tric-HCl 150 mM NaCl for C1* and C3* 
12 ml 200 mM Sodium Phosphate 300 mM NaCl for C2* and C4* 
4.5 ml 4 M NaCl for C1* and C4* pH 7.8  
9 ml 4 M NaCl for C2* and C4*    
pH 7.8 The buffer is filtered before use 
Protein L elution buffer SEC running buffer 
0.1 M Sodium Citrate 50 mM Tris-HCl 
pH 3 The buffer is filtered before use pH 7.8 The buffer is filtered  
                  and degassed before use 
S11 
 
Running buffer for agarose gel 
 
Staining and destaining solutions 
 
 
 
 
1x TAE-Running buffer (agarose gel)  
4.84 g Tris base    
1.14 g Acetic acid    
0.74 g EDTA * 2H2O    
MQ-H2O to final volume of 1 L  
Coomassie Blue staining solution Fixation mix-Silver staining 
0.05% Coomassie Blue 40% Ethanol 
10% Acetic Acid 10% Acetic acid 
25% 2-Propanol    
Farmer’s Reducer-Silver staining Silver nitrate solution-Silver staining 
1% 30 mM K3Fe(CN)6 0.1% AgNO3 
0.75% 30 mM Na2S2O3x 5 H2O    
Washing solution-Silver staining Developing solution-Silver staining 
2.5% Na2CO3 2.5% Na2CO3 
   0.1% Formaldehyde ( CH2O) 
Stop development solution-Silver staining  
10% Acetic acid   
S12 
Buffers used in ELISA and Western blotting 
 
 
 
 
 
 
 
1x PBS-T 1x PSB-TM – (5% milk) 
500 ml 1x PBS 50 ml 1x PBS-T 
0.5 ml Tween-20 2.5 g Dried skimmed milk 
 
ECF buffer-Western Transfer buffer-Western 
15 ml 5 M NaCl 15 g Glycine 
50 ml 1 M Tris pH 7.5 25 ml 1 M Tris pH 8.0 
MQ-H2O to a final volume of 0.5 L 200 ml Methanol 
   1 ml 20% SDS 
   MQ-H2O to a final volume of 1 L 
 
 
  
1x PBS 
0.8% NaCl 
0.02% KCl 
0.144% Na2HPO4 
0.024% KH4PO4 
pH 7.4 
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Section C: Restriction- and ligation reagents 
All reagents are listed in Table S1: Reagents 
Double-digest reactions: Cloning and subcloning the scFv constructs into pFKPEN 
 
Table S8: Digestion setup for cloning the C1 construct 
 
 
Table S9: Digestion setup controls NcoI and NotI for cloning the C1 construct 
 
  
Double digest reaction of pFKPEN: 
mother clone (vector) 
Double digest reaction for VH-LR-VL.A 
(insert) 
2.5 l  800 ng/l pFKPEN,  
mother clone 
10 l  200 ng/l VH-LR-VL.A 
3 l  Buffer #3  3 l  Buffer #3  
1 l  NcoI  1 l  NcoI  
1 l  NotI  1 l    NotI  
3 l  100x BSA 3 l  100x BSA 
19.5 l  MQ-H2O 19.5 l  MQ-H2O 
30 l   30 l   
Control digestion of pFKPEN, mother 
clone (vector) 
Control digestion of pFKPEN, mother 
clone (vector) 
2.5 l  800 ng/l pFKPEN,  
mother clone 
2.5 l  800 ng/l pFKPEN,  
mother clone 
3 l    Buffer #3  3 l  Buffer #3  
1 l  NcoI  1 l  NotI  
3 l  100x BSA  3 l  100x BSA  
20.5 l  MQ-H2O 20.5 l  MQ-H2O 
30 l l  30 l   
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Table S10: Digestion setup for subcloning the C2 construct 
 
 
Table S11: Digestion setup for subcloning the C4 construct 
 
  
Double digest reaction of pFKPEN: 
containing scFv C1 (vector) 
Double digest reaction for LC-VL (insert) 
10 l  290 ng/l pFKPEN, C1 20 l  100 ng/l LC-VL 
3 l  Buffer #3  3 l  Buffer #3 
1 l  MluI 1 l  MluI  
1 l  NotI 1 l  NotI 
3 l  100x BSA  3 l  100x BSA 
12 l  MQ-H2O 2 l  MQ-H2O 
30 l   30 l   
Double digest reaction of pFKPEN: 
containing scFv C1 (vector) 
Double digest reaction for LC-VL (insert) 
10 l  290 ng/l pFKPEN, C1 20 l  100 ng/l LC-VL 
3 l  Buffer #3  3 l  Buffer #3  
1.5 l  HindIII 1.5 l  HindIII 
1 l  NotI 1 l  NotI 
3 v  100x BSA  3 l  100x BSA 
10.5 l  MQ-H2O 1.5 l  MQ-H2O 
1 l  CIP    
30 l   30 l     
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Table S12: Digestion setup controls HindIII and NotI for subcloning the C2 and C4 construct
s 
 
 
Table S13: Digestion setup control MluI for subcloning the C2 and C4 constructs 
 
  
Control digestion of pFKPEN, C1 Control digestion of pFKPEN, C1 
5 l  290 ng/l pFKPEN, C1 5 l  290 ng/l pFKPEN, C1 
3 l  Buffer #3  3 l  Buffer #3  
1.5 l  HindIII 1 l  NotI  
3 l  100x BSA 3 l  100x BSA 
17.5 l  MQ-H2O 18 l  MQ-H2O 
30 l   30 l   
Control digestion of pFKPEN, C1  
5 l  290 ng/l pFKPEN, C1    
3 l  Buffer #3     
1 l  MluI    
3 l  100x BSA    
18 l  MQ-H2O    
30 l      
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Table S14: Digestion setup for subcloning the C3 construct 
 
 
Table S15: Digestion setup controls MluI and NotI for subcloning the C3 construct 
 
  
Double digest reaction of pFKPEN: 
containing scFv C4 (vector) 
Double digest reaction of pFKPEN: 
containing scFv C1 (insert) 
10 l  230 ng/l pFKPEN, C4 7 l  370 ng/l pFKPEN, C1  
3 l  Buffer #3  3 l  Buffer #3  
1 l  MluI  1 l  MluI  
1 l  NotI  1 l  NotI  
3 l  100x BSA 3 l  100x BSA 
12 l  MQ-H2O 15 l  MQ-H2O 
30    30 l   
Control digestion of pFKPEN, C4 Control digestion of pFKPEN, C4 
10 l  230 ng/l pFKPEN, C4 10 l  230 ng/l pFKPEN, C4 
3 l  Buffer #3  3 l  Buffer #3  
1 l  MluI  1 l  NotI  
3 l  100x BSA 3 l  100x BSA 
13 l  MQ-H2O 13 l  MQ-H2O 
30 l   30 l   
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Double-digest reactions: Removing the His-tag 
 
Table S16: Digestion setup of pFKPEN for subcloning of C1* C2*, C3* and C4* 
 
 
Table S17: Digestion setup for subcloning of C1 and C2* into the pFKPEN vector 
 
 
  
Double digest reaction of pFKPEN C3 
(vector) for subcloning of C1*, C2*, 
C3*and C4* 
 
3.6 l  560 ng/l pFKPEN, C3    
3 l  Buffer #3     
1.5 l  NcoI     
1.5 l  NotI     
3 l  100x BSA    
16.4 l  MQ-H2O    
1 l  CIP    
30 l      
Double digest reaction of PCR product 
C1* (insert) 
Double digest reaction of PCR product C2* 
(insert) 
13 l  152 ng/l PCR DNA: C1* 18 l  111 ng/l PCR DNA: C1* 
3 l  Buffer #3  3 l  Buffer #3  
1.5 l  NcoI  1.5 l  NcoI  
1.5 l  NotI  1.5 l  NotI  
3 l  100x BSA 3 l  100x BSA 
8 l  MQ-H2O 3 l  MQ-H2O 
30 l   30 l   
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Table S18: Digestion setup for subcloning of C3* and C4* into the pFKPEN vector 
 
 
Table S19: Digestion setup controls NcoI and NotI with pFKPEN for subcloning the C1*, C2
*, C3*, C4* constructs 
 
 
 
 
All restriction reactions were incubated at 37C for 1.5 hours.  
Double digest reaction of PCR product 
C3* (insert) 
Double digest reaction of PCR product C4* 
(insert) 
12 l  166 ng/l PCR DNA: C1* 11 l  180 ng/l PCR DNA: C1* 
3 l  Buffer #3  3 l  Buffer #3  
1.5 l  NcoI  1.5 l  NcoI  
1.5 l  NotI  1.5 l  NotI  
3 l  100x BSA 3 l  100x BSA 
9 l  MQ-H2O 10 l  MQ-H2O 
30    30 l   
Control digestion of pFKPEN, C3 Control digestion of pFKPEN, C3 
3.6 l  560 ng/l pFKPEN, C3 3.6 l  560 ng/l pFKPEN, C3 
3 l  Buffer #3  3 l  Buffer #3  
1.5 l  NcoI  1.5 l  NotI  
3 l  100x BSA 3 l  100x BSA 
17.9 l  MQ-H2O 17.9 l  MQ-H2O 
1 l  CIP 1 l  CIP 
30    30 l   
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Ligation reactions: Cloning and subcloning the scFv constructs into pFKPEN 
 
Table S20: Ligation setup for cloning the scFv C1 construct into pFKPEN 
 
 
Table S21: Ligation setup for subcloning of C2 into the pFKPEN vector 
 
  
4:1 ligation reaction of pFKPEN, mother 
clone (vector) and VH-LR-VL.A (insert) 
Negative control: Ligation reaction for 
pFKPEN, mother clone (vector)  
13 l 3.7 ng/µl VH-LR-VL.A, 815 bp  0 l Insert  
3 l 21 ng/µl pFKPEN, 39995 bp  3 l 21 ng/µl pFKPEN, 3995 bp  
2 l 10x ligation buffer  2 l 10x ligation buffer  
1 l T4 DNA ligase  1 l T4 DNA ligase  
1 l MQ-H2O 14l  MQ-H2O 
20 l  20 l  
4:1 ligation reaction of pFKPEN, C1 
(vector) and VL (insert) 
Negative control: Ligation reaction for 
pFKPEN, C1 (vector)  
5 l 3.9 ng/µl VL., 340 bp  0 l Insert  
5 l 13 ng/µl pFKPEN, C1, 4474 bp  5 l 13 ng/µl pFKPEN, C1, 4474 bp  
2 l 10x ligation buffer  2 l 10x ligation buffer  
1 l T4 DNA ligase  1 l T4 DNA ligase  
7 l MQ-H2O 7 l MQ-H2O 
20 l  20 l  
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Table S22: Ligation setup for subcloning of C4 into the pFKPEN vector 
 
 
Table S23: Ligation setup for subcloning of C3 into the pFKPEN vector 
 
  
4:1 ligation reaction of pFKPEN, C1 
(vector) and LC-VL (insert) 
Negative control: Ligation reaction for 
pFKPEN, C1 (vector)  
5.7 l  4.2 ng/µl VL., 396bp  0 l  Insert 
3 l 22.3 ng/µl pFKPEN, C1, 4418bp  3 l 22.3 ng/µl pFKPEN, C1, 4418bp  
2 l 10x ligation buffer  2 l 10x ligation buffer  
1 l T4 DNA ligase  1 l T4 DNA ligase  
8.3 l MQ-H2O 14 l MQ-H2O 
20 l  20 l  
4:1 ligation reaction of pFKPEN, C4 
(vector) and VL (insert) 
Negative control: Ligation reaction for 
pFKPEN, C4 (vector)  
3.4 l 3.5 ng/µl VL., 340 bp  0 l Insert 
13 l 3 ng/µl pFKPEN, C1, 4474 bp  13 l 3 ng/µl pFKPEN, C1, 4474 bp  
2 l 10x ligation buffer  2 l 10x ligation buffer  
1 l T4 DNA ligase  1 l T4 DNA ligase  
0.6 l MQ-H2O 4 l MQ-H2O 
20 l  20 l  
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Ligation reactions: Subcloning the scFv PCR fragments into pFKPEN 
 
Table S24: Ligation setup for subcloning of PCR product C1* and C2* into the pFKPEN 
vector 
 
Table S25: Ligation setup for subcloning of PCR product C3* and C4* into the pFKPEN 
vector 
 
  
4:1 ligation reaction of pFKPEN, C3 
(vector) and C1* (insert) 
4:1 ligation reaction of pFKPEN, C3 
(vector) and C2* (insert) 
1 l 38 ng/µl, C1*, 780 bp  1 l 40 ng/µl, C2*, 780 bp  
4 l 12.5 ng/µl pFKPEN, C1, 3995 bp  4 l 12.5 ng/µl pFKPEN, C1, 3995 bp  
2 l 10x ligation buffer  2 l 10x ligation buffer  
1 l T4 DNA ligase  1 l T4 DNA ligase  
12  
l 
MQ-H2O 12 l MQ-H2O 
20 l  20 l  
4:1 ligation reaction of pFKPEN, C3 
(vector) and C3* (insert) 
4:1 ligation reaction of pFKPEN, C3 
(vector) and C4* (insert) 
1 l 40 ng/µl, C2*, 780 bp  2 l 20 ng/µl, C2*, 780 bp  
4 l 12.5 ng/µl pFKPEN, C1, 3995 bp  4 l 12.5 ng/µl pFKPEN, C1, 3995 bp  
2 l 10x ligation buffer  2 l 10x ligation buffer  
1 l T4 DNA ligase  1 l T4 DNA ligase  
12 l MQ-H2O 11 l MQ-H2O 
20 l  20 l  
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Table S26: Ligation setup control for the subcloning of the PCR DNA fragments into vector 
pFKPEN 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
All ligation samples are incubated overnight at room temperature  
Negative control: ligation reaction for 
pFKPEN, C3 (vector)  
 
0 l Insert    
4 l 12.5 ng/µl pFKPEN, C1, 3995 bp     
2 l 10x ligation buffer     
1 l T4 DNA ligase     
12 l MQ-H2O    
20 l     
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Section D: PCR mixtures and PCR programs 
All reagents are listed in Table S1: Reagents 
Table S27: PCR mixture for amplification of circular pFKPEN containing the scFv constructs 
36.1 µl MQ-H2O 
10 µl 5x Phusion HF buffer  
2 µl 5 mM dNTP  
0.2 µl 100 µM forward primer 
0.2 µl 100 µM reverse primer 
1 µl 40 ng/ µl pFKPEN containing the scFv construct 
0.5 µl 2U/ µl Phusion DNA polymerase  
50 µl  
 
Table S28: PCR program for circular pFKPEN containing the scFv constructs 
  
1x Initial melting 98 C 1 minute 
28x Denaturation 98 C 10 seconds 
 Annealing 60 C 15 seconds 
 Elongation 72 C 20 seconds 
1x Final elongation 72 C 5 minutes 
 Maintain 4 C  
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Section E: Nucleic acid sequences 
 
The restriction sites are underlined. 
DNA sequence of C1 (819 bp) 
1 GCCATGGCCCACCACCACCACCACCACGAAAACCTGTACTTCCAGGGTCA 
51       GGTGCAGCTGCAGCAGAGCGGCGCGGAACTGGCGAAACCGGGCGCGAGCA 
101 TGAAAATGAGCTGCCGCGCGAGCGGCTATAGCTTTACCAGCTATTGGATT 
151 CATTGGCTGAAACAGCGCCCGGATCAGGGCCTGGAATGGATTGGCTATAT 
201 TGATCCGGCGACCGCGTATACCGAAAGCAACCAGAAATTTAAAGATAAAG 
251 CGATTCTGACCGCGGATCGCAGCAGCAACACCGCGTTTATGTATCTGAAC 
301 AGCCTGACCAGCGAAGATAGCGCGGTGTATTATTGCGCGCGCGAAAGCCC 
351 GCGCCTGCGCCGCGGCATTTATTATTATGCGATGGATTATTGGGGCCAGG 
401 GCACCACCGTGACCGTGAGCAGCAAGCTTTCAGGGAGTGCATCCGCCCCA 
451 AAACTTGAAGAAGGTGAATTTTCAGAAGCACGCGTAGACATCCAGATGAC 
501 CCAGACCCCGTCTTCTCTGTCTGCTTCTCTGGGTGACCGTGTTACCATCT 
551 CTTGCCGTGCTTCTCAGGACATCTCTAACTACCTGAACTGGTACCAGCAG 
601 AAACCGGACGGTACCGTTAAACTGCTGATCTACTACACCTCTCGTCTGCA 
651 CTCTGGTGTTCCGTCTCGTTTCTCTGGTTCTGGTTCTGGTACCGACTACT 
701 CTCTGACCATCTCTAACCTGGAACAGGAAGACATCGCTACCTACTTCTGC 
751 CAGCAGGGTAACACCCTGCCGCCGACCTTCGGTGCTGGTACCAAACTGGA 
801 ACTGAAATAAGCGGCCGCT 
 
DNA sequence of C1* (780bp) 
1 GCCATGGCCCAGGTGCAGCTGCAGCAGAGCGGCGCGGAACTGGCGAAACC 
51 GGGCGCGAGCATGAAAATGAGCTGCCGCGCGAGCGGCTATAGCTTTACCA 
101 GCTATTGGATTCATTGGCTGAAACAGCGCCCGGATCAGGGCCTGGAATGG 
151 ATTGGCTATATTGATCCGGCGACCGCGTATACCGAAAGCAACCAGAAATT 
201 TAAAGATAAAGCGATTCTGACCGCGGATCGCAGCAGCAACACCGCGTTTA 
251 TGTATCTGAACAGCCTGACCAGCGAAGATAGCGCGGTGTATTATTGCGCG 
301 CGCGAAAGCCCGCGCCTGCGCCGCGGCATTTATTATTATGCGATGGATTA 
351 TTGGGGCCAGGGCACCACCGTGACCGTGAGCAGCAAGCTTTCAGGGAGTG 
401 CATCCGCCCCAAAACTTGAAGAAGGTGAATTTTCAGAAGCACGCGTAGAC 
451 ATCCAGATGACCCAGACCCCGTCTTCTCTGTCTGCTTCTCTGGGTGACCG 
501 TGTTACCATCTCTTGCCGTGCTTCTCAGGACATCTCTAACTACCTGAACT 
551 GGTACCAGCAGAAACCGGACGGTACCGTTAAACTGCTGATCTACTACACC 
601 TCTCGTCTGCACTCTGGTGTTCCGTCTCGTTTCTCTGGTTCTGGTTCTGG 
651 TACCGACTACTCTCTGACCATCTCTAACCTGGAACAGGAAGACATCGCTA 
701 CCTACTTCTGCCAGCAGGGTAACACCCTGCCGCCGACCTTCGGTGCTGGT 
751 ACCAAACTGGAACTGAAATAAGCGGCCGCT  
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DNA sequence of C2 (819 bp) 
1 GCCATGGCCCACCACCACCACCACCACGAAAACCTGTACTTCCAGGGTCA 
51       GGTGCAGCTGCAGCAGAGCGGCGCGGAACTGGCGAAACCGGGCGCGAGCA 
101 TGAAAATGAGCTGCCGCGCGAGCGGCTATAGCTTTACCAGCTATTGGATT 
151 CATTGGCTGAAACAGCGCCCGGATCAGGGCCTGGAATGGATTGGCTATAT 
201 TGATCCGGCGACCGCGTATACCGAAAGCAACCAGAAATTTAAAGATAAAG 
251 CGATTCTGACCGCGGATCGCAGCAGCAACACCGCGTTTATGTATCTGAAC 
301 AGCCTGACCAGCGAAGATAGCGCGGTGTATTATTGCGCGCGCGAAAGCCC 
351 GCGCCTGCGCCGCGGCATTTATTATTATGCGATGGATTATTGGGGCCAGG 
401 GCACCACCGTGACCGTGAGCAGCAAGCTTTCAGGGAGTGCATCCGCCCCA 
451 AAACTTGAAGAAGGTGAATTTTCAGAAGCACGCGTAGACCTGGTTCTGAC 
501 CCAGTCTCCGGCTACCCTGTCTGTTACCCCAGGTGACTCTGTTTCTTTCT 
551 CTTGCCGTGCTTCTCAGTCTATCTCTAACAACCTGCACTGGTACCAGCAG 
601 CGTACCCACGAATCTCCGCGTCTGCTGATCAAATACGCTTCTCAGTCTAT 
651 CTCTGGTATCCCGTCTCGTTTCTCTGGTTCTGGTTCTGGTACCGACTTCA 
701 CCCTGTCTATCTCTTCTGTTGAAACCGAAGACTTCGGTATGTACTTCTGC 
751 CAGCAGTCTAACCGTTGGCCGCTGACCTTCGGTGCTGGTACCAAACTGGA 
851 ACTGAAATAAGCGGCCGCT 
 
DNA sequence of C2* (780bp) 
1 GCCATGGCCCAGGTGCAGCTGCAGCAGAGCGGCGCGGAACTGGCGAAACC 
51 GGGCGCGAGCATGAAAATGAGCTGCCGCGCGAGCGGCTATAGCTTTACCA 
101 GCTATTGGATTCATTGGCTGAAACAGCGCCCGGATCAGGGCCTGGAATGG 
151 ATTGGCTATATTGATCCGGCGACCGCGTATACCGAAAGCAACCAGAAATT 
201 TAAAGATAAAGCGATTCTGACCGCGGATCGCAGCAGCAACACCGCGTTTA 
251 TGTATCTGAACAGCCTGACCAGCGAAGATAGCGCGGTGTATTATTGCGCG 
301 CGCGAAAGCCCGCGCCTGCGCCGCGGCATTTATTATTATGCGATGGATTA 
351 TTGGGGCCAGGGCACCACCGTGACCGTGAGCAGCAAGCTTTCAGGGAGTG 
401 CATCCGCCCCAAAACTTGAAGAAGGTGAATTTTCAGAAGCACGCGTAGAC  
451 CTGGTTCTGACCCAGTCTCCGGCTACCCTGTCTGTTACCCCAGGTGACTC 
501 TGTTTCTTTCTCTTGCCGTGCTTCTCAGTCTATCTCTAACAACCTGCACT 
551 GGTACCAGCAGCGTACCCACGAATCTCCGCGTCTGCTGATCAAATACGCT 
601 TCTCAGTCTATCTCTGGTATCCCGTCTCGTTTCTCTGGTTCTGGTTCTGG 
651 TACCGACTTCACCCTGTCTATCTCTTCTGTTGAAACCGAAGACTTCGGTA 
701 TGTACTTCTGCCAGCAGTCTAACCGTTGGCCGCTGACCTTCGGTGCTGGT 
751 ACCAAACTGGAACTGAAATAAGCGGCCGCT  
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DNA sequence of C3 (819 bp) 
1 GCCATGGCCCACCACCACCACCACCACGAAAACCTGTACTTCCAGGGTCA 
51       GGTGCAGCTGCAGCAGAGCGGCGCGGAACTGGCGAAACCGGGCGCGAGCA 
101 TGAAAATGAGCTGCCGCGCGAGCGGCTATAGCTTTACCAGCTATTGGATT 
151 CATTGGCTGAAACAGCGCCCGGATCAGGGCCTGGAATGGATTGGCTATAT 
201 TGATCCGGCGACCGCGTATACCGAAAGCAACCAGAAATTTAAAGATAAAG 
251 CGATTCTGACCGCGGATCGCAGCAGCAACACCGCGTTTATGTATCTGAAC 
301 AGCCTGACCAGCGAAGATAGCGCGGTGTATTATTGCGCGCGCGAAAGCCC 
351 GCGCCTGCGCCGCGGCATTTATTATTATGCGATGGATTATTGGGGCCAGG 
401 GCACCACCGTGACCGTGAGCAGCAAGCTTGCGCCGCAGGCGAAAAGCAGC 
451     GGCAGCGGCAGCGAAAGCAAAGTGGATGCACGCGTAGACATCCAGATGAC 
501 CCAGACCCCGTCTTCTCTGTCTGCTTCTCTGGGTGACCGTGTTACCATCT 
551 CTTGCCGTGCTTCTCAGGACATCTCTAACTACCTGAACTGGTACCAGCAG 
601 AAACCGGACGGTACCGTTAAACTGCTGATCTACTACACCTCTCGTCTGCA 
651 CTCTGGTGTTCCGTCTCGTTTCTCTGGTTCTGGTTCTGGTACCGACTACT 
701 CTCTGACCATCTCTAACCTGGAACAGGAAGACATCGCTACCTACTTCTGC 
751 CAGCAGGGTAACACCCTGCCGCCGACCTTCGGTGCTGGTACCAAACTGGA 
801 ACTGAAATAAGCGGCCGCT 
 
DNA sequence of C3* (780bp) 
1 GCCATGGCCCAGGTGCAGCTGCAGCAGAGCGGCGCGGAACTGGCGAAACC 
51 GGGCGCGAGCATGAAAATGAGCTGCCGCGCGAGCGGCTATAGCTTTACCA 
101 GCTATTGGATTCATTGGCTGAAACAGCGCCCGGATCAGGGCCTGGAATGG 
151 ATTGGCTATATTGATCCGGCGACCGCGTATACCGAAAGCAACCAGAAATT 
201 TAAAGATAAAGCGATTCTGACCGCGGATCGCAGCAGCAACACCGCGTTTA 
251 TGTATCTGAACAGCCTGACCAGCGAAGATAGCGCGGTGTATTATTGCGCG 
301 CGCGAAAGCCCGCGCCTGCGCCGCGGCATTTATTATTATGCGATGGATTA 
351 TTGGGGCCAGGGCACCACCGTGACCGTGAGCAGCAAGCTTGCGCCGCAGG 
401    CGAAAAGCAGCGGCAGCGGCAGCGAAAGCAAAGTGGATGCACGCGTAGAC 
451 ATCCAGATGACCCAGACCCCGTCTTCTCTGTCTGCTTCTCTGGGTGACCG 
501 TGTTACCATCTCTTGCCGTGCTTCTCAGGACATCTCTAACTACCTGAACT 
551 GGTACCAGCAGAAACCGGACGGTACCGTTAAACTGCTGATCTACTACACC 
601 TCTCGTCTGCACTCTGGTGTTCCGTCTCGTTTCTCTGGTTCTGGTTCTGG 
651 TACCGACTACTCTCTGACCATCTCTAACCTGGAACAGGAAGACATCGCTA 
701 CCTACTTCTGCCAGCAGGGTAACACCCTGCCGCCGACCTTCGGTGCTGGT 
751 ACCAAACTGGAACTGAAATAAGCGGCCGCT  
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DNA sequence of C4 (819 bp) 
1 GCCATGGCCCACCACCACCACCACCACGAAAACCTGTACTTCCAGGGTCA 
51       GGTGCAGCTGCAGCAGAGCGGCGCGGAACTGGCGAAACCGGGCGCGAGCA 
101 TGAAAATGAGCTGCCGCGCGAGCGGCTATAGCTTTACCAGCTATTGGATT 
151 CATTGGCTGAAACAGCGCCCGGATCAGGGCCTGGAATGGATTGGCTATAT 
201 TGATCCGGCGACCGCGTATACCGAAAGCAACCAGAAATTTAAAGATAAAG 
251 CGATTCTGACCGCGGATCGCAGCAGCAACACCGCGTTTATGTATCTGAAC 
301 AGCCTGACCAGCGAAGATAGCGCGGTGTATTATTGCGCGCGCGAAAGCCC 
351 GCGCCTGCGCCGCGGCATTTATTATTATGCGATGGATTATTGGGGCCAGG  
401 GCACCACCGTGACCGTGAGCAGCAAGCTTGCGCCGCAGGCGAAAAGCAGC 
451 GGCAGCGGCAGCGAAAGCAAAGTGGATGCACGCGTAGACCTGGTTCTGAC 
501 CCAGTCTCCGGCTACCCTGTCTGTTACCCCAGGTGACTCTGTTTCTTTCT 
551 CTTGCCGTGCTTCTCAGTCTATCTCTAACAACCTGCACTGGTACCAGCAG 
601 CGTACCCACGAATCTCCGCGTCTGCTGATCAAATACGCTTCTCAGTCTAT 
651 CTCTGGTATCCCGTCTCGTTTCTCTGGTTCTGGTTCTGGTACCGACTTCA 
701 CCCTGTCTATCTCTTCTGTTGAAACCGAAGACTTCGGTATGTACTTCTGC 
751 CAGCAGTCTAACCGTTGGCCGCTGACCTTCGGTGCTGGTACCAAACTGGA 
851 ACTGAAATAAGCGGCCGCT 
 
DNA sequence of C4* (780bp) 
1 GCCATGGCCCAGGTGCAGCTGCAGCAGAGCGGCGCGGAACTGGCGAAACC 
51 GGGCGCGAGCATGAAAATGAGCTGCCGCGCGAGCGGCTATAGCTTTACCA 
101 GCTATTGGATTCATTGGCTGAAACAGCGCCCGGATCAGGGCCTGGAATGG 
151 ATTGGCTATATTGATCCGGCGACCGCGTATACCGAAAGCAACCAGAAATT 
201 TAAAGATAAAGCGATTCTGACCGCGGATCGCAGCAGCAACACCGCGTTTA 
251 TGTATCTGAACAGCCTGACCAGCGAAGATAGCGCGGTGTATTATTGCGCG 
301 CGCGAAAGCCCGCGCCTGCGCCGCGGCATTTATTATTATGCGATGGATTA 
351 TTGGGGCCAGGGCACCACCGTGACCGTGAGCAGCAAGCTTGCGCCGCAGG 
401    CGAAAAGCAGCGGCAGCGGCAGCGAAAGCAAAGTGGATGCACGCGTAGAC 
451 CTGGTTCTGACCCAGTCTCCGGCTACCCTGTCTGTTACCCCAGGTGACTC 
501 TGTTTCTTTCTCTTGCCGTGCTTCTCAGTCTATCTCTAACAACCTGCACT 
551 GGTACCAGCAGCGTACCCACGAATCTCCGCGTCTGCTGATCAAATACGCT 
601 TCTCAGTCTATCTCTGGTATCCCGTCTCGTTTCTCTGGTTCTGGTTCTGG 
651 TACCGACTTCACCCTGTCTATCTCTTCTGTTGAAACCGAAGACTTCGGTA 
701 TGTACTTCTGCCAGCAGTCTAACCGTTGGCCGCTGACCTTCGGTGCTGGT 
751 ACCAAACTGGAACTGAAATAAGCGGCCGCT  
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PCR-primers for Oligonucleotide-directed mutagenesis  
Forward (NcoI restriction site underlined): 
 5’-ATATCCATGGCCCAGGTGCAGCTGCAGCAG-3’ 
 
Reverse (NotI restriction site underlined): 
 (5’-TATAGCGGCCGCTTATTTCAGTTCCAGTTTGG-3’)  
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Section F: Amino acid sequences  
 
ClustalW2, EMBL-EBI alignment of the four scFv nucleotide sequence  
(Larkin et al., 2007).  
 
The VH is not marked and starts form nucleotide 7 to 423. 
The VL is not marked and starts from nucleotide 486 to 810 
The VL.A is marked in light grey:  ATCG 
The LC linker is marked in medium grey:  ATCG 
The LR linker is marked in dark grey: ATCG 
The restriction sites are marked in black:  ATCG 
 
 
C1              GCCATGGCCCACCACCACCACCACCACGAAAACCTGTACTTCCAGGGTCAGGTGCAGCTG 60 
C2              GCCATGGCCCACCACCACCACCACCACGAAAACCTGTACTTCCAGGGTCAGGTGCAGCTG 60 
C3              GCCATGGCCCACCACCACCACCACCACGAAAACCTGTACTTCCAGGGTCAGGTGCAGCTG 60 
C4              GCCATGGCCCACCACCACCACCACCACGAAAACCTGTACTTCCAGGGTCAGGTGCAGCTG 60 
                ************************************************************ 
 
C1              CAGCAGAGCGGCGCGGAACTGGCGAAACCGGGCGCGAGCATGAAAATGAGCTGCCGCGCG 120 
C2              CAGCAGAGCGGCGCGGAACTGGCGAAACCGGGCGCGAGCATGAAAATGAGCTGCCGCGCG 120 
C3              CAGCAGAGCGGCGCGGAACTGGCGAAACCGGGCGCGAGCATGAAAATGAGCTGCCGCGCG 120 
C4              CAGCAGAGCGGCGCGGAACTGGCGAAACCGGGCGCGAGCATGAAAATGAGCTGCCGCGCG 120 
                ************************************************************ 
 
C1              AGCGGCTATAGCTTTACCAGCTATTGGATTCATTGGCTGAAACAGCGCCCGGATCAGGGC 180 
C2              AGCGGCTATAGCTTTACCAGCTATTGGATTCATTGGCTGAAACAGCGCCCGGATCAGGGC 180 
C3              AGCGGCTATAGCTTTACCAGCTATTGGATTCATTGGCTGAAACAGCGCCCGGATCAGGGC 180 
C4              AGCGGCTATAGCTTTACCAGCTATTGGATTCATTGGCTGAAACAGCGCCCGGATCAGGGC 180 
                ************************************************************ 
 
C1              CTGGAATGGATTGGCTATATTGATCCGGCGACCGCGTATACCGAAAGCAACCAGAAATTT 240 
C2              CTGGAATGGATTGGCTATATTGATCCGGCGACCGCGTATACCGAAAGCAACCAGAAATTT 240 
C3              CTGGAATGGATTGGCTATATTGATCCGGCGACCGCGTATACCGAAAGCAACCAGAAATTT 240 
C4              CTGGAATGGATTGGCTATATTGATCCGGCGACCGCGTATACCGAAAGCAACCAGAAATTT 240 
                ************************************************************ 
 
C1              AAAGATAAAGCGATTCTGACCGCGGATCGCAGCAGCAACACCGCGTTTATGTATCTGAAC 300 
C2              AAAGATAAAGCGATTCTGACCGCGGATCGCAGCAGCAACACCGCGTTTATGTATCTGAAC 300 
C3              AAAGATAAAGCGATTCTGACCGCGGATCGCAGCAGCAACACCGCGTTTATGTATCTGAAC 300 
C4              AAAGATAAAGCGATTCTGACCGCGGATCGCAGCAGCAACACCGCGTTTATGTATCTGAAC 300 
                ************************************************************ 
 
C1              AGCCTGACCAGCGAAGATAGCGCGGTGTATTATTGCGCGCGCGAAAGCCCGCGCCTGCGC 360 
C2              AGCCTGACCAGCGAAGATAGCGCGGTGTATTATTGCGCGCGCGAAAGCCCGCGCCTGCGC 360 
C3              AGCCTGACCAGCGAAGATAGCGCGGTGTATTATTGCGCGCGCGAAAGCCCGCGCCTGCGC 360 
C4              AGCCTGACCAGCGAAGATAGCGCGGTGTATTATTGCGCGCGCGAAAGCCCGCGCCTGCGC 360 
                ************************************************************ 
 
C1              CGCGGCATTTATTATTATGCGATGGATTATTGGGGCCAGGGCACCACCGTGACCGTGAGC 420 
C2              CGCGGCATTTATTATTATGCGATGGATTATTGGGGCCAGGGCACCACCGTGACCGTGAGC 420 
C3              CGCGGCATTTATTATTATGCGATGGATTATTGGGGCCAGGGCACCACCGTGACCGTGAGC 420 
C4              CGCGGCATTTATTATTATGCGATGGATTATTGGGGCCAGGGCACCACCGTGACCGTGAGC 420 
                ************************************************************ 
 
C1              AGCAAGCTTTCAGGGAGTGC-ATCCGCCCCAAAACTTGAAGAAGGTGAATTTTCAGAAGC 479 
C2              AGCAAGCTTTCAGGGAGTGC-ATCCGCCCCAAAACTTGAAGAAGGTGAATTTTCAGAAGC 479 
C3              AGCAAGCTTGCGCCGCAGGCGAAAAGCAGCGGCAGCGGCAGCGAAAGCAAAGTG-GATGC 479 
C4              AGCAAGCTTGCGCCGCAGGCGAAAAGCAGCGGCAGCGGCAGCGAAAGCAAAGTG-GATGC 479 
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                ********* *.  *.. ** *:..**. *...*   *.**....:*.*:: *  **:** 
  
C1              ACGCGTAGACATCCAGATGACCCAGACCCCGTCTTCTCTGTCTGCTTCTCTGGGTGACCG 539 
C2              ACGCGTAGACCTGGTTCTGACCCAGTCTCCGGCTACCCTGTCTGTTACCCCAGGTGACTC 539 
C3              ACGCGTAGACATCCAGATGACCCAGACCCCGTCTTCTCTGTCTGCTTCTCTGGGTGACCG 539 
C4              ACGCGTAGACCTGGTTCTGACCCAGTCTCCGGCTACCCTGTCTGTTACCCCAGGTGACTC 539 
                **********.*  : .********:* *** **:* ******* *:* * .******   
 
C1              TGTTACCATCTCTTGCCGTGCTTCTCAGGACATCTCTAACTACCTGAACTGGTACCAGCA 599 
C2              TGTTTCTTTCTCTTGCCGTGCTTCTCAGTCTATCTCTAACAACCTGCACTGGTACCAGCA 599 
C3              TGTTACCATCTCTTGCCGTGCTTCTCAGGACATCTCTAACTACCTGAACTGGTACCAGCA 599 
C4              TGTTTCTTTCTCTTGCCGTGCTTCTCAGTCTATCTCTAACAACCTGCACTGGTACCAGCA 599 
                ****:* :******************** . *********:*****.************* 
 
C1              GAAACCGGACGGTACCGTTAAACTGCTGATCTACTACACCTCTCG-TCTGCACTCTGGTG 658 
C2              GCGTACCCACGAATCTCCGCGTCTGCTGATCAAATACGCTTCTCAGTCT-ATCTCTGGTA 658 
C3              GAAACCGGACGGTACCGTTAAACTGCTGATCTACTACACCTCTCG-TCTGCACTCTGGTG 658 
C4              GCGTACCCACGAATCTCCGCGTCTGCTGATCAAATACGCTTCTCAGTCT-ATCTCTGGTA 658 
                *..:.*  ***.::*    ..:*********:*.***.* ****. *** .:*******. 
 
C1              TTCCGTCTCGTTTCTCTGGTTCTGGTTCTGGTACCGACTACTCTCTGACCATCTCTAACC 718 
C2              TCCCGTCTCGTTTCTCTGGTTCTGGTTCTGGTACCGACTTCACCCTGTCTATCTCTTCTG 718 
C3              TTCCGTCTCGTTTCTCTGGTTCTGGTTCTGGTACCGACTACTCTCTGACCATCTCTAACC 718 
C4              TCCCGTCTCGTTTCTCTGGTTCTGGTTCTGGTACCGACTTCACCCTGTCTATCTCTTCTG 718 
                * *************************************:*:* ***:* ******:.   
 
C1              TGGAACAGGAAGACATCGCTACCTACTTCTGCCAGCAGGGTAACACCCTGCCGCCGACCT 778 
C2              TTGAAACCGAAGACTTCGGTATGTACTTCTGCCAGCAGTCTAACCGTTGGCCGCTGACCT 778 
C3              TGGAACAGGAAGACATCGCTACCTACTTCTGCCAGCAGGGTAACACCCTGCCGCCGACCT 778 
C4              TTGAAACCGAAGACTTCGGTATGTACTTCTGCCAGCAGTCTAACCGTTGGCCGCTGACCT 778 
                * ***.. ******:*** **  ***************  ****.    ***** ***** 
 
C1              TCGGTGCTGGTACCAAACTGGAACTGAAATAAGCGGCCGCT 819 
C2              TCGGTGCTGGTACCAAACTGGAACTGAAATAAGCGGCCGCT 819 
C3              TCGGTGCTGGTACCAAACTGGAACTGAAATAAGCGGCCGCT 819 
C4              TCGGTGCTGGTACCAAACTGGAACTGAAATAAGCGGCCGCT 819 
                ***************************************** 
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Section G: Crystallisation screens 
Original conditions for crystallisation hits 
Morpheus screen condition C8 0.5 M Buffer, 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 
12.5% w/v PEG MPD, 0.03 M of each NPS, pH 7.8 
C1* (1.6 mg/ml) with ~10x Tricer stored at 4 °C 
Morpheus screen condition G8: 0.5 M Buffer, 12.5% w/v PEG 1000, 12.5% w/v PEG 3350, 
12.5% w/v PEG MPD, 0.02 M of each carboxyl acid, pH 7.8 C1* (1.6 mg/ml) with 
~10x Tricer stored at 4 °C 
Table S29: Optimised Morpheus screen C8. The parameter that is varied from the original 
condition is marked in bold. C1 contains the original conditions 
 
  
 1 2 3 
A 0.5 M Buffer, pH 6.5 
12.5% w/v PEG 1000 
12.5% w/v PEG 3350 
12.5% w/v MPD  
0.03 M of each NPS: 
 
0.5 M Buffer, pH 7.5 
12.5% w/v PEG 1000 
12.5% w/v PEG 3350 
12.5% w/v MPD  
- 
 
0.5 M Buffer, pH 7.5 
38.75% PEG 1000 (50%) 
- 
- 
-0.03 M of each NPS: 
 
B 0.5 M Buffer, pH 7.0 
12.5% w/v PEG 1000 
12.5% w/v PEG 3350 
12.5% w/v MPD  
0.03 M of each NPS: 
 
0.5 M Buffer, pH 7.5 
12.5% w/v PEG 1000 
12.5% w/v PEG 3350 
12.5% w/v MPD  
1 M Sodium Nitrate 
 
0.1 ml Buffer, pH 7.5 
- 
30% PEG 3350 
- 
0.03 M of each NPS: 
 
C 0.5 M Buffer, pH 7.5 
12.5% w/v PEG 1000 
12.5% w/v PEG 3350 
12.5% w/v MPD  
0.03 M of each NPS: 
 
0.5 M Buffer, pH 7.5 
12.5% w/v PEG 1000 
12.5% w/v PEG 3350 
12.5% w/v MPD  
1 M Ammonium 
sulphate 
 
0.1 ml Buffer, pH 7.5 
- 
- 
35% PEG MME 
0.03 M of each NPS: 
 
D 0.5 M Buffer, pH 8.0 
12.5% w/v PEG 1000 
12.5% w/v PEG 3350 
12.5% w/v MPD  
0.03 M of each NPS: 
 
0.5 M Buffer, pH 7.5 
12.5% w/v PEG 1000 
12.5% w/v PEG 3350 
12.5% w/v MPD  
0.5 M Sodium 
phosphate  
 
0.1 ml Buffer, pH 7.5 
- 
- 
30% ml MPD 
0.03 M of each NPS: 
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Table S30 Optimised Morpheus screen G8. The parameter that is varied from the original 
condition is marked in bold. C1 contains the original conditions 
 4 5 6 
A 0.5 M Buffer, pH 6.5 
12.5% w/v PEG 1000 
12.5% w/v PEG 3350 
12.5% w/v MPD  
0.02 M of each carboxy
l acid 
 
0.5 M Buffer, pH 7.5 
12.5% w/v PEG 1000 
12.5% w/v PEG 3350 
12.5% w/v MPD - 
- 
 
0.1 ml Buffer, pH 7.5 
38.75% PEG 1000  
- 
- 
0.02 M of each carboxyl acid: 
 
B 0.5 M Buffer, pH 7.0 
12.5% w/v PEG 1000 
12.5% w/v PEG 3350 
12.5% w/v MPD  
0.02 M of each carboxy
l acid 
 
0.5 M Buffer, pH 7.5 
12.5% w/v PEG 1000 
12.5% w/v PEG 3350 
12.5% w/v MPD  
1 M ammonium acetate 
 
0.1 ml Buffer, pH 7.5 
- 
30% PEG 3350 
- 
0.02 M of each carboxyl acid 
 
C 0.5 M Buffer, pH 7.5 
12.5% w/v PEG 1000 
12.5% w/v PEG 3350 
12.5% w/v MPD  
0.02 M of each carboxy
l acid: 
 
0.5 M Buffer, pH 7.5 
12.5% w/v PEG 1000 
12.5% w/v PEG 3350 
12.5% w/v MPD 
1 M sodium potassium l
-tartrate 
 
0.1 ml Buffer, pH 7.5 
- 
- 
35% PEG MME- 
0.02 M of each carboxyl acid 
 
D 0.5 M Buffer, pH 8.0 
12.5% w/v PEG 1000 
12.5% w/v PEG 3350 
12.5% w/v MPD  
0.02 M of each carboxy
l acid: 
 
0.5 M Buffer, pH 7.5 
12.5% w/v PEG 1000 
12.5% w/v PEG 3350 
12.5% w/v MPD 
0.5 M sodium oxamate 
 
0.1 ml Buffer, pH 7.5 
- 
- 
30% MPD 
0.02 M of each carboxyl acid 
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Optimisation, crystallisation hits 
The number system refers to crystallisation conditions in Table S29 and Table S30. 
50% protein: 
Crystals: 
1D (several very small crystals) 
2A (1 crystal and precipitation) 
2C (several very small crystals) 
2D (several small crystals and precipitation) 
4D (several small crystals), 5B (two, larger crystals), 
5D (several small crystals) 
Precipitation: 
1A, 1B, 2B, 3B, 3C, 4B, 4C, 5C, 6B, 
 
25% protein: 
Crystals: 
1A (several small crystals, and one larger) 
1D (1 larger crystal and presentation)  
2D (1 small crystal and precipitation)  
4A (three small crystals) 
5D (precipitation and 1 larger crystal) 
Precipitation: 
1B, 1C, 2A, 2B, 2C, 2C,3A, 3B, 3C, 3D 4B, 4C, 4D, 5A, 5B, 5C 
 
 
  
S34 
 
Section H: Vector  
The original pFKPEN model was created by Geir Åge Løset (Centre for Immune Regulation 
and Department of Biosciences, University of Oslo, Norway), in this version the scFv have 
been sketched into the multiple cloning site. 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
